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ABSTRACT 
Funding strategies for providing genetic testing in the province of British 
Columbia are examined, including alternate forms of publicly funding the B.C. Molecular 
Genetics Laboratory (MGL), privatization of the MGL, and outsourcing of testing to 
private laboratories.  Demand scenarios are constructed and costs of supplying genetic 
testing estimated for different scenarios.  Public funding of MGL is more efficient at 
providing genetic tests in all scenarios except the most optimistic private funding 
scenario. 
Funding MGL through public funds using at least a partial per-test funding 
strategy provides B.C. with reasonably priced genetic testing for the near future, an 
internal source of genetic test provision and development, and capacity to expand and 
provide genetic testing to clients inside and outside B.C.  All of these contribute to the 
benefit of the people and province of British Columbia while operating in a fiscally and 
medically prudent manner. 
 
 
  iv 
EXECUTIVE SUMMARY 
Project Overview & Aim 
British Columbia’s Molecular Genetics Laboratory (MGL) develops and provides 
diagnostic testing for congenital anomalies and genetic diseases in foetuses, children, and 
adults.  MGL has a history of constrained funding and a consequent provincial 
outsourcing of samples resulting in reduced benefits and higher costs to the province. 
The aim of this project is threefold: to establish a balanced five-year funding 
strategy for MGL; to reduce out-of-province expenses; and to present and justify a 
strategy to sustainably fund genetic testing in B.C. for the future. 
MGL Funding and Demand 
MGL is currently funded via hospital-level global funding, capped by strategic 
plan at 2002/3 levels.  With no adjustment to funding since 2003, available funds for 
laboratory supplies and reagents have been severely reduced by increasing labour costs 
while test demand has risen steadily.  MGL has succeeded in meeting rising demand 
despite reduced supply funding via operational efficiencies and repurposing of available 
funds, but MGL’s Director feels the limit of operational efficiencies has been reached. 
With future demand expected to rise, constant global funding is unsustainable 
over the next five years.  I explore the costs and scalability of different funding models 
including per-test funding, privatization of MGL, and outsourcing genetic testing to 
private laboratories. 
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Conclusions 
The province is best served by MGL through a per-test funding strategy in which 
MGL’s budget is at least partially proportional to the number and cost of tests performed.  
Per-test funding for MGL provides cheaper access to services than either privatizing 
MGL or outsourcing genetic testing to private companies. 
Instituting per-test funding for MGL allows expansion of services through 
addition of new tests.  New tests proposed by Director of the MGL Dr. Brett Casey and 
approved in June 2008 will provide a 45% demand increase and increase referred-in 
revenue.  By developing in-house versions of tests often sent out-of-country, OOC 
payments will drop significantly. 
Per-test funding for MGL ensures that MGL will be able to supply expanded 
services within the province and to out-of-province clients for the near-term future.  By 
2013, MGL will be performing 2 to 7 times as many tests annually as in fiscal 2008 at a 
total cost of $1.9 - $6M. 
Recommendations 
1. Transition MGL to a funding strategy in which salaries and maintenance contracts 
are provided through hospital global funding and increase annually with step 
increases and promotions.  Provide supply funding on a per-test basis starting at 
$50/test.  Update per-test payments rapidly as test type, test frequency, and test 
cost information become available. 
2. Centralize MSP’s tracking, administration, and approval of genetic testing inside 
and outside B.C. to collect test type, test frequency, and test cost tracking 
information to improve decision-making about tests to develop and provide in-
province.  MGL would be a logical place to perform this tracking. 
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GLOSSARY 
Alzheimer’s Disease Degenerative brain disease, the most common form of 
dementia. 
Amyotrophic Lateral 
Sclerosis (ALS), Sporadic 
Progressive degeneration of motor neurons.  “Sporadic” 
indicates random or isolated cases 
Babesia Tick-borne protozoan parasites. 
Bordetella Aerobic bacteria, including Bordetella pertussis, the cause 
of whooping cough 
Borellia Borellia burgdorferi is a spirochete bacteria, the cause of 
Lyme Disease 
C&W B.C. Children’s & Women’s Health Centre 
Charcot-Marie-Tooth Progressive genetic peripheral neuropathy, characterized by 
degeneration of nerves’ myelin sheath 
Connexin 26 Genetic cause of hearing loss due to disrupted potassium 
flow. 
Craniosynostosis Birth defect in which the bones of the skull join before full 
brain growth, resulting in abnormal skull shape and brain 
growth. 
Crohn’s Disease Inflammatory gastric disease 
Cystic Fibrosis Genetic disorder characterized by excess mucus production 
in the respiratory tract and dysfunction of the exocrine 
glands 
CYP2D6 Gene position for Cytochrome P-450 2D6 enzyme, 
responsible for metabolizing certain drugs. 
Cytochrome P-450 Family of oxidizing enzymes present in many organisms.  
Some of the enzymes metabolize or clear drugs. 
  xiii 
DNA DeoxyriboNucleic Acid.  The molecular coding mechanism 
for genetic information, held in the nucleus of cells.  A 
double-stranded molecule joined by weak connections. 
DNA Extraction Process by which DNA is collected and purified from a 
sample. 
Ehrlichia Small bacteria that attack leukocytes (white blood cells) and 
cause Ehrlichiosis, a disease with symptoms including fever, 
headache, malaise, and muscle aches. 
Exon Separated DNA portion of a gene with multiple physical 
sections 
Fragile X Syndrome Most frequent cause of mental retardation.  Often 
characterized by macroorchidism, large, prominent ears, and 
a long narrow face. 
FTE Full Time Employee or Full Time Equivalent 
Gene The physical unit of heredity.  A specific region (or 
separated regions) of a chromosome.  Composed of DNA 
Genome Complete genetic information for an individual 
Genomics The study and use (science) of genomes 
Genotype The genetic information for an individual or cell 
Haemoglobin (C, S) Haemoglobin is the oxygen-transporting molecule in blood.  
C and S refer to abnormalities.  S is the most common 
haemoglobin abnormality and is the basis of sickle cell trait 
and anaemia. 
Haemophilia A X-linked disorder, deficiency of coagulation factor VIII.  
Characterized by haemorrhages and failure of blood to clot 
Hereditary Hemorrhagic 
Telangiectasia (HHT) 
Genetic disorder characterized by abnormal blood vessels. 
HLA-DRB1 Part of the major histocompatibility complex, responsible 
for portions of the human immune system and autoimmune 
disorders. 
Ichthyosis, X-Linked Genetic disorder characterized by scaling of the skin. 
  xiv 
Likely Cases (LCs) Statistically calculated number of cases of a disorder, 
determined by multiplying the size of a population and 
prevalence of the disorder in that population 
Long QT Syndrome 
(LQTS) 
Cardiac syndrome characterized by fainting (syncope), a 
long QT interval in the EKG, and risk of sudden death by 
ventricular arrhythmia.  Several genetic markers exist for 
LQTS. 
Lou Gehrig’s Disease See Amyotrophic Lateral Sclerosis (ALS), Sporadic 
Marfan Syndrome Hereditary disorder of connective tissue.   
MGL B.C. Molecular Genetics Laboratory at B.C. Children’s & 
Women’s Health Centre 
MoH B.C. Ministry of Health 
MSP B.C. Medical Services Plan 
Mycobacterium Family of bacteria, including Mycobacterium tuberculosis, 
which causes tuberculosis, and Mycobacterium leprae, 
which causes Hansen’s Disease 
Mycoplasma Group of bacteria lacking a cell wall, conferring resistance 
to some antibiotics that attack the cell wall.  Includes 
Mycoplasma pneumoniae, which causes respiratory 
diseases. 
Neurofibromatosis 
(Type 1, Type 2) 
Two common genetic disorders. Spots, freckling, and 
fibrous tumours on nerve cells characterize Type 1.  Type 2 
is usually limited to the acoustic nerve and central nervous 
system. 
OOC Out-of-Country 
OOP Out-of-Province 
Pharmacogenomics Designing and developing drugs targeted to individuals with 
specific genetic (genomic) characteristics. 
Phenotype Characteristics displayed by an individual 
PHSA Provincial Health Services Authority of B.C.  
  xv 
Prevalence Frequency of disease in a population 
Sequencing Processing DNA to determine the order (sequence) of base 
pairs.  Reading the information in the DNA. 
SNP Single Nucleotide Polymorphism 
Sporadic Amyotrophic 
Lateral Sclerosis (ALS) 
See Amyotrophic Lateral Sclerosis (ALS), Sporadic 
Thalassemia (α, β) Inherited haemoglobin disorders. 
X-Linked Ichthyosis See Ichthyosis, X-Linked 
Zygosity Determining whether siblings of a multiple birth are 
identical (monozygotic or from a single fertilized egg) or 
fraternal (di- or poly-zygotic or from multiple fertilized 
eggs). 
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1 PROJECT OVERVIEW 
1.1 Context 
The Molecular Genetics Laboratory (MGL) at the British Columbia Children’s & 
Women’s Health Centre is British Columbia’s primary laboratory for gene based testing.  
MGL develops and provides diagnostic testing for congenital anomalies and genetic 
diseases in foetuses, children, and adults.1 
MGL is cost-constrained and has been “chronically underfunded despite rapidly 
increasing demand”.2  A one-time proposal for increased funding was approved in 20083 
but no provision has been made for sustainable long-term funding. 
According to Dr. Brett Casey, Director of the MGL, 200 samples were referred 
out-of-province for testing in fiscal 2007.  Without the recent funding increase, an 
estimated 400 samples, costing $300K, would have been referred out in fiscal 2007/8.4  
The long-run trend is an increasing shortfall of internal funding and an increasing number 
of samples referred out. 
1.2 Aim 
This analysis will address three goals: 
                                                
1 B.C. Children's Hospital. (2007). B.C. Children's Hospital Strategic Plan 2007. Retrieved 2008.08.10, 
from http://www.bcchildrens.ca/AboutUs/default.htm 
2 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services, pg 4 
3 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services, pg 4 
4 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services, pg 4 
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• Establish a balanced five-year funding strategy for MGL 
• Reduce out-of-province (referred out) expenses 
• Present and justify a sustainable approach to genetic testing funding in British 
Columbia 
1.3 Scope 
Options and recommendations will be limited to: 
• Genetic testing for inherited diseases 
• Testing for the benefit of the people and province of British Columbia 
• Organizational characteristics of the MGL, including funding and ownership 
• Capabilities of the MGL 
• A five-year time horizon 
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2 FUNDING THE B.C. MOLECULAR GENETICS 
LABORATORY 
In order to exploit the benefits of genetic and genomic medicine, the province of 
B.C. must have the capability to do DNA-based testing.  The MGL at C&W is the 
province’s primary lab for doing DNA-based testing.  Choices made about funding MGL 
will affect the efficacy of genetic testing and treatment in B.C. for the foreseeable future. 
2.1 MGL Services 
MGL offers DNA-based genetic tests for hereditary diseases to residents of B.C. 
through the Ministry of Health’s Medical Services Plan.  In addition, MGL facilitates 
out-of-country (OOC) testing for tests that MGL cannot perform for capacity reasons, 
supply reasons, or through not yet having developed a test.  All of MGL’s testing is 
diagnostic, meaning that it directly affects the treatment of a patient.  Predictive testing 
(tests which indicate the likelihood of having or acquiring a condition) is not performed 
at MGL because predictive testing is not covered under the provincial MSP. 
2.1.1 Mission 
MGL lacks a formal mission statement, but the Provincial Medical Genetics 
Program “…is committed to providing high quality genetic health care to residents of 
  4 
B.C., while participating in and contributing actively to research and education in the 
field of Medical Genetics.”5 
MGL’s participation in this mission is the creation and execution of DNA-based 
diagnostic tests, and the facilitation of out-of-province testing.  Research into the 
identifying of genes and their connections to diseases is not part of MGL’s participation.  
MGL takes in research as an input and outputs a test. 
2.1.2 Tests 
MGL offers a menu of 41 DNA-based diagnostic tests for a variety of hereditary 
genetic diseases and 2 generic DNA-based tests (DNA extraction and zygosity testing).  
As of June 2008, MGL is working on adding ten new DNA-based diagnostic tests for 
hereditary genetic diseases.  These new tests are responsible for the most out-of-province 
requests and the highest out-of-province costs and represent approximately 10% of all 
tests performed in fiscal 20086. 
2.1.3 Benefits 
Genetic testing provides diagnostic confirmation (or differential diagnosis) of 
many conditions requiring treatment.  The Medical Services Commission specifies that 
“Genetic testing is an insured service in British Columbia only when it is medically 
necessary to the medical management of the beneficiary's condition”7, which specifically 
                                                
5 B.C. Children's Hospital. (2007). B.C. Children's Hospital Strategic Plan 2007. Retrieved 2008.08.10, 
2008, from http://www.bcchildrens.ca/AboutUs/default.htm 
6 See Appendix B: C&W Molecular Genetics Test Menu on page 63 for a table of currently offered tests 
and Appendix F: June 2008 Tests to be Added, on page 70 for a table of new tests planned. 
7 Medical Services Commission. (2006). Medical Services Commission Out of Province and Out of 
Country Medical Care Guidelines for Funding Approval. Retrieved 2008.07.05, from 
http://www.health.gov.bc.ca/msp/infoben/ooc_funding_guidelines.pdf, pg 5 
  5 
excludes predictive testing and limits covered tests to those which assist a clinician in 
determining treatment.  Every test performed by MGL on a sample from B.C. directly 
affects treatment of a patient in B.C. 
2.2 MGL Funding 
MGL is funded through the Ministry of Health as part of the Children’s & 
Women’s Health Centre of British Columbia (C&W).  The 2007 strategic plan for C&W 
assumes a continuing funding cap at fiscal 2002/2003 levels8. 
2.3 Mismatch 
MGL’s budget for laboratory supplies (chemical reagents and other consumables) 
has been declining sharply over the last five years.  The available supply budget projected 
for fiscal 2007/8 is only 27% of fiscal 2004.  Partly as a result of decreased laboratory 
supplies, the number of samples sent out-of-country (OOC) has risen from an estimated 
90 in 2005/6 to a projected 400 in 2007/8.  The cost of OOC samples has risen from 
approximately $70K to nearly $300K.9 
                                                
8 B.C. Children's Hospital. (2007). B.C. Children's Hospital Strategic Plan 2007. Retrieved 2008.08.10, 
from http://www.bcchildrens.ca/AboutUs/default.htm  
9 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services 
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Figure 1: Supply Funding vs. Out-of-Country Costs 
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3 STAKEHOLDERS 
Stakeholders are defined as “[p]eople who will be affected by the project or can 
influence it but who are not directly involved with doing the project work.”10  
Organizations or people who potentially will be affected by or can influence MGL’s 
services and funding include: 
• Funding organizations (C&W, MSP, potential future clients); 
• Test providers (competing and complementary laboratories); 
• Test consumers (doctors, laboratories, individuals); 
• Test developers (testing firms, laboratories) 
In order to determine which stakeholders are likely to be affected by MGL’s 
funding and which can influence MGL’s funding strategy, I will evaluate each category 
of stakeholder for influence in two directions: the organization or individual’s influence 
upon MGL and MGL’s funding strategy; and MGL’s influence upon the organization or 
individual.  By finding the high influence stakeholders, recommendations can be 
evaluated from their point of view and in terms of their interests as well as MGL’s 
interests and point of view. 
3.1 Funding Organizations 
In accordance with The Golden Rule of Economics, “[h]e that has the gold makes 
the rules”11, funding organizations usually have great influence upon decision-making.  
                                                
10 Olson, D. & samagaio. (2003). Term Definition: Stakeholder. Retrieved 2008.07.05  
11 “He that has the gold makes the rules” is in common usage, attributed at least once to Lyndon Foreman.  
There are many similar variants. 
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The negative form “the power to tax involves the power to destroy”12 more clearly 
expresses the power of monetary influence.  The organizations providing budget funds to 
the MGL now and in the future are those most likely to influence organizational 
decisions. 
Whether those organizations are tightly cohesive will dramatically affect their 
influence.  Current funding comes from two major locations: C&W global funding and 
MSP out of country (OOC) funding.  The separation of these two sources (even under the 
overall umbrella of the B.C. Ministry of Health) reduces the cohesiveness of the funding 
plan and almost certainly introduces inefficiencies.  For example, capacity at the MGL is 
presently artificially limited by a declining supply budget (provided by C&W global 
funding) while out-of-country genetic testing costs rise dramatically (provided by MSP 
OOC funding).  Since OOC costs rise considerably more than the cost of doing those 
tests at MGL13, the Ministry of Health spends more money on genetic testing than 
necessary.  Despite this, the Ministry of Health has enormous organizational and market 
power over MGL. 
Potential future funding sources include organizations and individuals outside 
B.C.  Categorized collectively as “potential future clients”, they have almost no overall 
organizational cohesion and little market power over MGL.  Future clients represent the 
largest opportunity14 to expand MGL’s market, but that market is only indirectly related 
                                                
12 Webster, D. & Marshall, J. (1989). 1798: Daniel Webster (1782 - 1852). Retrieved 2008.07.05, Daniel 
Webster, arguing before the US Supreme Court in McCulloch v. Maryland: “An unlimited power to tax 
involves, necessarily, a power to destroy,” 17 U.S. 327 (1819).  Chief Justice John Marshall’s decision in 
McCulloch v. Maryland: “That the power to tax involves the power to destroy … [is] not to be denied”. 
13 See Section 5.2, Current and Future Test Costs by Funding Method on page 46 for detailed cost and price 
information. 
14 See Section 4.5, Detailed Examination of Demand on page 37 for demand scenarios. 
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to the Provincial Medical Genetics Program’s mission “to provid[e] high quality genetic 
health care to residents of B.C….” [italics mine].  
3.1.1 B.C. Children’s & Women’s Health Centre 
B.C. Children’s & Women’s Health Centre (C&W) is operated by the Provincial 
Health Services Authority (PHSA) under the auspices of the Ministry of Health.  MGL is 
physically co-located with C&W and currently depends upon C&W for primary funding 
to cover facilities, personnel, and supplies. 
C&W represents a primary barrier to organizational change at MGL.  As a 
practical matter, any changes to MGL funding will have to be supported by C&W.  Any 
proposed changes to MGL funding will have to provide benefits to C&W or, at worst, be 
neutral to C&W.  MGL performs only about ¼ of 1% of the tests done annually at 
C&W15 and is therefore below the radar for most decisions at C&W.  Considering their 
respective sizes, MGL might do well to present changes that will decrease C&W’s 
involvement in decisions about MGL to reduce MGL’s effect upon C&W’s attention 
overhead. 
C&W’s influence over MGL decision-making is high.  The effect of changes at 
MGL on C&W is likely to be low. 
                                                
15 B.C. Children's Hospital. (2007). B.C. Children's Hospital Strategic Plan 2007. Retrieved 2008.08.10, 
http://www.bcchildrens.ca/AboutUs/default.htm, pg 5; and Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: Final Business Case for Clinical Services. 
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3.1.2 B.C. Ministry of Health 
The B.C. Ministry of Health is responsible for delivering healthcare services to 
the residents of British Columbia.  With a $13 billion budget16 (fiscal 2007/8 estimate), 
the Ministry of Health represents nearly 35% of the total expenditures by the provincial 
government of B.C.17  The Ministry of Health provides funding for MGL through two 
distinct pathways: Out-of-Country funding via the Medical Services Plan (MSP) and 
hospital global funding through Children’s & Women’s Health Centre (C&W). 
3.1.2.1  Out-of-Country funding 
The B.C. Medical Services Plan (MSP) offers limited coverage of expenses 
incurred out-of-province or out-of-country, generically referred to as Out of Country 
(OOC) care.  The Medical Services Commission (MSC) publishes guidelines for out-of-
country services.18  The guidelines make provision for non-emergency out-of-country 
care including “Laboratory and Medical Imaging Tests” and “Genetic Tests”19, which 
establish three conditions before OOC expenses for testing are covered: 
1. The tests must not be experimental.  This is roughly equivalent to requiring 
that only drugs in the B.C. PharmaCare formulary be covered. 
2. Diagnostic alternatives within B.C. and Canada must be exhausted. 
3. The test must significantly alter management of the patient’s condition. This 
condition specifies that the test must provide information necessary for 
                                                
16 B.C. Ministry of Health. (2007). 2007/08 ‐ 2009/10 Service Plan: Resource Summary. Retrieved 2008.07.22, http://www.bcbudget.gov.bc.ca/2007/sp/hlth/default.html#9 
17 Public Affairs Bureau. (2008). Balanced Budget 2008 Backgrounder. Retrieved 2008.08.10, http://www.bcbudget.gov.bc.ca/2008/backgrounders/backgrounder_fiscal_plan.htm 
18 Medical Services Commission. (2006). Medical Services Commission Out of Province and Out of 
Country Medical Care Guidelines for Funding Approval. Retrieved 2008.07.05, 
http://www.health.gov.bc.ca/msp/infoben/ooc_funding_guidelines.pdf 
19 See Appendix H: MSC Guidelines on Genetic Tests on page 73 
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diagnosis of a treatable syndrome or information necessary to establish which 
of several treatments are preferable. 
In fiscal 2006/7, the MSP approved roughly 200 out-of-country samples for 
payment.  Before the approval of expanded funding in 2007/8, the estimate for fiscal 
2007/8 was 400 samples outsourced at a cost of approximately $300K.  Although the cost 
seems high in relation to MGL’s budget, the OOC cost is a very small fraction20 of MSPs 
annual budget, and is apparently below the radar for improving efficiency.  As genetic 
medicine becomes more mainstream and more diagnostic (as opposed to predictive), it’s 
likely that these costs will rise, possibly dramatically and quickly.  MSP has the ability to 
control whether or not they fund OOC testing, but the acceptability and value of genetic 
testing is largely out of MSP’s control and thus represents a real budgetary risk, as the 
cost of an OOC test averages several times that of a test performed at MGL21. 
MSP’s influence on MGL’s funding is high from MGL’s point of view.  
Obtaining access to the OOC expenses currently predicted would add approximately 50% 
to MGL’s funding.  From MSP’s point of view, MGL’s funding requirements are low and 
MGL’s influence upon funding decisions is low to none. This low influence from MGL 
provides a reason for the long delay22 in reassessing MGL’s declining supply budget. 
                                                
20 According to the B.C. Ministry of Health Resource Summary for 2007/8, MGL’s expanded budget 
represents approximately 1/10 of 1% of MSP funding and personnel. B.C. Ministry of Health. (2007). 
2007/08 - 2009/10 Service Plan: Resource Summary. Retrieved 2008.07.22, 
http://www.bcbudget.gov.bc.ca/2007/sp/hlth/default.html#9 
21 See Section 5.2, Current and Future Test Costs by Funding Method on page 46 for detailed information 
on MGL costs and pricing of tests from outside laboratories. 
22 Anecdotally, funding changes at the MGL have been pursued for roughly four years, and only achieved 
in the summer of 2008.  
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3.1.2.2 MSP 
Blood tests in B.C. are either on an inpatient or outpatient basis.  Inpatient tests 
are funded through hospital global funding.  Outpatient tests are conducted either by 
public hospitals or private laboratories.  Approximately 1/3 of outpatient tests are 
performed by public hospital labs, with private labs accounting for the remaining 2/3. 
Outpatient blood tests by hospital or private labs are funded by MSP on a per-test basis.23 
If testing at MGL were to be funded as outpatient testing instead of inpatient 
testing, MSP’s influence on MGL funding would remain high.  The effect of changes at 
MGL on MSP is likely to be low to none so long as MGL remains owned by the 
government of B.C.  If MGL were privatized or genetic testing outsourced, the cost of 
testing to the Ministry of Health would almost certainly rise.  The influence upon the 
Ministry would depend upon the rise in cost, but would  start as low to none. 
In an ideal organization, there would be no difference between the MSP and the 
MSP Out-of-Country payment program.  Practically speaking, genetic testing costs are a 
minimal drain upon the MSP and the OOC program and there is little urgency to curtail 
them24.  Interdepartmental inefficiency raises the cost of providing genetic testing 
because the budget spent on OOC genetic tests can buy far more tests done by MGL in-
province.  A coordinating office for genetic testing (probably at MGL, which already 
facilitates OOC genetic tests) would be better able to track test types, frequency, and 
                                                
23 Bayne, L. (2003). BC Laboratory Services Review. Retrieved 2008.07.05, 
http://www.health.gov.bc.ca/library/publications/year/2003/lab_review.pdf, pg 20 
24 According to the B.C. Ministry of Health Resource Summary for 2007/2008, MGL’s expanded budget 
represents approximately 1/10 of 1% of MSP funding and personnel.  Any changes at MGL are unlikely 
to have a significant effect upon the MSP or the OOC program. B.C. Ministry of Health. (2007). 2007/08 
- 2009/10 Service Plan: Resource Summary. Retrieved 2008.07.22, 
http://www.bcbudget.gov.bc.ca/2007/sp/hlth/default.html#9 
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costs, as well as reducing inefficiencies introduced by the current dual-agency funding of 
genetic tests depending upon the location of the lab doing the test. 
3.1.3 Potential future clients 
Potential future clients include individuals, laboratories, doctors, and 
organizations providing healthcare, such as provincial health authorities, insurance 
companies, hospitals, etc.  Potential products include existing tests, newly developed 
tests, and licenses to perform tests developed at MGL. 
Unless large organizations come to dominate MGL’s future clientele (unlikely, 
since the B.C. Ministry of Health is likely to always be MGL’s largest source of funds), 
potential future clients outside B.C. will have low to no influence upon MGL’s funding 
or decision-making.25  Potential future clients within B.C. may have considerable 
influence as genetic medicine becomes mainstream and genomics becomes affordable.  
However, the aggregate influence of demand within B.C. should already be represented 
by the influence of MSP (and through MSP, the Ministry of Health) and MGL’s mission.  
The effect of changes at MGL on potential future clients will depend on what new 
services MGL brings on-line and whether those services are available elsewhere.  If new 
services are merely substitutes for ones available elsewhere, MGL’s effect upon potential 
future clients will be low to none.  If new services offered by MGL are unique, the effect 
upon potential future clients could be anything up to high.  
                                                
25 MGL’s mission is to provide genetic testing services to the residents of B.C. (my emphasis), according to 
B.C. Women's Hospital & Health Centre. (2008). Medical Genetics. Retrieved 2008.06.27 
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3.2 Test Providers (Competitors and Complementors) 
Test providers include publicly and privately owned laboratories.  Several 
publicly owned facilities in B.C. have labs that offer services similar to (and potentially 
overlapping) MGL’s: 
• Biochemical and Cytogenetics Laboratories at C&W 
• Molecular and Cytogenetics Laboratory at B.C Cancer Agency 
• PHSA Laboratories 
While these labs use various technologies for testing, it is the diagnostic effect 
rather than the technology that makes them (in some cases) viable substitutes.  Because 
all the public labs are (officially) cooperative with each other, it is generally a 
combination of minimal cost and clinician choice as to which lab is used.  B.C. Cancer 
Agency labs concentrate on cancer (e.g. the breast cancer susceptibility genes BCRA1 
and BCRA2) and not generalized genetic testing.  The Biochemical and Cytogenetics 
Labs at C&W extensively use non-DNA-based testing to achieve similar results.  Many 
current and future genetic tests have no non-DNA-based alternatives. 
Privately owned labs, regardless of location, are in competition with MGL to the 
extent that they offer similar services.  The influence of other labs on MGL funding is the 
extent to which stakeholders believe private labs represent a cost saving to MSP.  The 
effect of changes at MGL upon competing labs will be dependent upon the increased 
volume of testing MGL performs.  That effect is likely to be low. 
3.3 Test Consumers 
Individually, test consumers have little market power or influence upon MGL 
funding.  Collectively, doctors are MGL’s primary customer and will have the greatest 
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influence, laboratories are secondary, and individual patients will be tertiary.  Overall, I 
expect consumers to have much lower influence upon MGL than funding organizations. 
MGL’s services will have a medium to high effect upon consumers, particularly patients. 
3.3.1 Clinicians 
Doctors order genetic tests for diagnostic purposes.  In keeping with the MSP 
guidelines, genetic tests are only covered (and thus generally only ordered by doctors) 
“when it is medically necessary to the medical management of the beneficiary's 
condition”.26  Genetic testing remains relatively rare in B.C., and changes to the system 
will have low to no effect upon clinicians.  Clinicians have little effect upon MGL,27 via 
aggregated test demand28. 
3.3.2 Labs 
Currently labs (inside or outside the province) are unlikely to order genetic tests 
from MGL.  In the future, as MGL brings more tests on-line and offers those tests to non-
MSP organizations on a for-profit basis, outside labs may become a significant portion of 
MGL’s clientele.  Labs may represent two different revenue streams: direct orders for 
testing and requests to license tests developed by MGL. 
                                                
26 Medical Services Commission. (2006). Medical Services Commission Out of Province and Out of 
Country Medical Care Guidelines for Funding Approval. Retrieved 2008.07.05, 
http://www.health.gov.bc.ca/msp/infoben/ooc_funding_guidelines.pdf, pg 5 
27 It’s a valid point to argue that the real influence upon MGL is not the clinicians, but the genetic disorders, 
and their frequencies, but it is the clinicians who (properly instructed by medical schools and medical 
literature) recognize the diagnostic need for genetic tests. 
28 Demand is a very indirect influence in a government organization, especially a small portion of a popular 
governmental institution.  More direct is MGL’s mission to provide genetic testing for the benefit of 
residents in B.C.  Demand would be a far more direct influence to a privately owned laboratory. 
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MGL’s effect upon labs will be low to none, rising as MGL offers more tests to 
outside providers.  Labs’ effects upon MGL will be volume dependent — as volume of 
tests delivered to any given lab increases, so will the Lab’s effect upon MGL. 
3.3.3 Patients 
Assuming a change in policy regarding patient requests for genetic tests, some 
test requests will undoubtedly come directly from patients.  The volume of such requests 
(and thus the influence upon MGL) is likely to be low.  The effect of such testing upon 
individual patients will likely be high or at least medium (or they wouldn’t be going to 
the effort of ordering tests themselves).  If MSP policy regarding predictive testing were 
to change, direct test demand from patients would increase. 
3.4 Test Developers 
Test Developers have almost no influence upon MGL.  MGL chooses to develop 
tests for two reasons: 1) because the test is demanded by clinicians in the province and 
must be referred-out or doesn’t exist; or 2) because the test is widely in demand and 
would result in referred-in revenue.  In the first case the presence or absence of the test is 
irrelevant.  When developing a test exclusively to generate referred-in revenue, level of 
demand is more important than existence (that is, an additional test for a very prevalent 
condition might be more in demand than a first test for a low prevalence condition).  
MGL similarly has quite low influence upon other Test Developers.  Only under special 
conditions might a newly developed test significantly affect another laboratory. 
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3.5 Summary 
It’s clear from Table 1 on page 18 that the Funding Organizations (C&W, MSP 
OOC, & MSP) are the critical decision-makers for MGL funding.  They are the only high 
influence organizations and MGL has no significant reciprocal influence upon any of 
them, which explains why increasing MGL’s funding took four years.  The primary 
influence of all these organizations is to increase the quality and efficiency (and decrease 
the cost) of health care in B.C.  When a clear win (better service for about the same 
money) was properly presented, it was accepted. 
Because the MSP and MSP OOC have the same influences and ultimate goals, I 
will consider them under the umbrella of MSP from now on.  C&W represents the most 
significant barrier to organizational change at MGL.  C&W must be consulted about and 
approving of changes in MGL’s funding strategy. 
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Stakeholder(s) Effect upon MGL MGL’s Effect Upon 
Funding Organizations   
C & W High Low 
MSP OOC High Low  None 
MSP High Low  None 
Potential Future Clients Low  None High  None29 
Test Providers   
Publicly Owned Low Low 
Competitive Low Volume Dependent30 
Test Consumers   
Clinicians Low (Demand Dependent) Low  None 
Laboratories Volume Dependent Low  None 
Patients Low Medium  High 
Non-patient Consumers 
within B.C. 
Demand Dependent31 Low  Medium 
Non-patient Consumers 
outside B.C.  
Low  None32 Low  Medium 
Test Developers Low Low33 
Table 1: Stakeholder Influence (Summary) 
                                                
29 Depends upon (and is positively correlated with) uniqueness of services offered. 
30 Depends upon the relationship between volume of new tests at MGL and volume of competing 
laboratory. 
31 If (when) genome sequencing becomes commonplace, there will be an enormous change in demand. 
32 MGL’s mission is limited to supporting genetic testing for the residents of B.C. 
33 Depends upon the relationship between tests developed at MGL and provided by other Test Developers. 
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4 DETAILED EXAMINATION OF MGL 
The Molecular Genetic Laboratory (MGL) at B.C. Children’s & Women’s Health 
Centre is the province’s primary lab for DNA-based testing for hereditary diseases.  MGL 
performed approximately 5000 tests in fiscal 2007/8 and facilitated out-of-province 
testing for about 400 additional samples.  MGL’s budget has been constant since fiscal 
2002/3 but demand has more than doubled since then.  Operational efficiencies have 
allowed MGL to satisfy rising demand but Dr. Casey (Director, MGL) believes that 
opportunities for operational efficiencies have been exhausted without additional 
personnel and equipment34.  MGL must expand capacity to meet the province’s rising 
demand for DNA-based testing. 
In order to determine what funding strategy is best for MGL and the province, I 
examine MGL’s position in the provincial health care system, the services MGL 
provides, how MGL is currently funded, a variety of alternate funding options, and 
demand for MGL’s services. 
4.1 Overview of MGL 
MGL operates as a stand-alone unit within the B.C. Children’s & Women’s 
Health Centre in Vancouver, B.C., and performs a variety of tests for genetic disorders.  
MGL contributes to the Ministry of Health’s overall mission of providing sustainable, 
affordable health care for the residents of B.C. while operating within the requirements of 
the Medical Services Committee’s requirements for non-experimental testing.  Because 
                                                
34 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services
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genetic testing is a fast-changing field of study, requirements for additions to MGL’s 
menu of tests may happen quickly.  Using mission statements and published goals, I will 
establish a set of criteria by which future decisions can be evaluated.  
4.1.1 Mission 
MGL has and supports missions, goals, and objectives for several levels of 
organization in the province35.  It’s important to compare alternate scenarios with 
organizational visions, missions, goals, and objectives firmly in mind.  MGL’s primary 
roles in these missions, goals, and objectives are creating and performing DNA-based 
diagnostic tests and facilitating out-of-province genetic testing.  Decision criteria for 
alternatives thus include whether or not (or to what extent) the alternatives contribute to: 
• High quality genetic health care 
• Diagnostic consultation and services on which vital decisions are made in the care 
of patients 
• [Helping individuals] make healthy lifestyle choices 
• Protection of the public from preventable disease, illness, and injury 
• Sustainable, affordable, publicly funded health system 
• Sound business practices 
These criteria break down into two categories: 
• Health Care Related: High quality genetic health care consists of diagnostic 
testing which allow clinicians to make decisions affecting the care of patients or 
patients to make healthy lifestyle choices to protect themselves (the public) from 
preventable disease, illness, and injury. 
• Business Related: High quality genetic health care uses sound business practices 
to contribute to a sustainable, affordable, publicly funded health system. 
                                                
35 Appendix G: Mission Statements and Goals on page 71 lists specific missions, goals, and objectives for 
organizations to which MGL is responsible. 
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4.1.1.1 Decision Criteria 
While there are many possible criteria derivable from the above mission and goal 
statements, I present mine for this project.  Each element is evaluated by asking: 
1. Does it promote diagnostic testing? 
2. Does it allow… 
a. clinicians to make decisions affecting the care of patients? or 
b. patients to make healthy lifestyle choices? 
3. Does it protect the public from preventable disease, illness, and injury? 
4. Is it a sound business practice? 
5. Is it sustainable and affordable in the short and long-term? 
6. Does it promote a publicly funded health system? 
The first three are health care related and generally fall outside this project’s 
scope.  It is sufficient to note that the initial selection of a test must meet these criteria: be 
diagnostic (not predictive); make a difference to care or lifestyle choices of a patient; and 
protect the public (patients) from preventable disease, illness, or injury. 
4.1.1.2 Decision Criteria and Stakeholders 
How do the important stakeholders (funding organizations) consider these 
criteria?  Only C&W is in the day-to-day business of directly providing healthcare, so 
they will regard Criteria 1 – 3 as more important, while the MSP will have at least some 
concern for business issues. 
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Criteria C&W MSP Sum 
1. Diagnostic Testing ++ + (OOC) +++ 
2a. Clinical Decisions ++ + (OOC) +++ 
2b. Patient Decisions + O + 
3. Protect Public + + ++ 
4. Sound Business Practice O + + 
5. Sustainable & Affordable O ++ ++ 
6. Public Funding O ++ ++ 
Table 2: Importance of decision criteria to current funding organization stakeholders 
As a rule, the bureaucratic organization will be more concerned with business 
practices, but MSP OOC involves itself in questions of whether tests are diagnostic and 
whether they affect clinical decisions.  C&W, being closer to the patient, will concern 
itself less with long-term questions of business and sustainability than effective treatment.  
Between them, the two organizations (C&W and MSP) consider all the decision criteria 
at least somewhat important.  I will address the business issues (Criteria 4 – 6) and leave 
the medical criteria to the medical experts. 
4.1.2 Location 
MGL is located at the B.C. Children’s Hospital, 4480 Oak Street, Vancouver, 
B.C.  Vancouver B.C. is a biotech cluster with multiple research institutions, life science 
associations, bioinformatics firms, biopharmaceutical firms, and supporting infrastructure 
including consultants, contract laboratories, and manufacturers.36  MGL is co-located 
with B.C. Children’s Hospital because of history and the number of pre-natal and 
childhood tests performed.   
                                                
36 LifeSciencesBC. (2008). LifeSciences BC Member Profiles by Sector. Retrieved 2008.06.29, 
http://www.lifesciencesbc.ca/Members/Member_Company_Profiles/Members_by_Sector2.asp 
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4.1.3 Staff 
Dr. Brett Casey has been Director of the MGL since 2001, and is also head of the 
Program in Laboratory Genetics at B.C. Children’s Hospital.  Dr. Casey performed his 
residency in Anatomic and Clinical Pathology at the University of California at San 
Diego and fellowships in Human Molecular Genetics and Paediatric Pathology at Baylor 
College of Medicine and Texas Children’s Hospital in Houston, Texas.  
Dr. Casey’s molecular genetics experience covers a wide range of applications, 
and his research has focused on malformation syndromes in humans.  He is a Diplomate 
of the American Boards of Pathology and Medical Genetics and Pathology and is a 
Fellow of both the Canadian and American Colleges of Medical Genetics.37 
The functional staff of the MGL consists of 3.5 FTE technologists.  With the 
recently approved funding, additional functional staff will be hired to 5 FTE 
technologists. 
Employee turnover in the MGL is very low. 
4.1.4 Funding History MGL was first established in 1990, funded by the provincial Medical Service Plan (MSP) via the Alternative Payments Branch.  This funding continued through 2002.  
In B.C.’s fiscal 2004, apparently because genetic testing was becoming mainstream, 
MGL’s budget allocation was transferred to the Children’s & Women’s Health Centre 
(C&W).38 
                                                
37 Casey, B. (2008). Re: [Sustainable Funding Analysis] Collected Questions 
38 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services 
  24 
MGL’s total operating budget is divided into professional salaries and supplies 
and operating expenses.  Professional salaries rise over time and a constant overall budget 
thus leads to a declining supplies budget.  Since fiscal 2003/4, MGL’s supplies budget 
has declined from nearly $90K to near $25K, a reduction of almost 2/3.  In fiscal 2007/8, 
MGL’s supplies budget was returned to $100K and supplemented by $93K in referred-in 
revenue. 
4.2 Detailed Examination of Services 
MGL’s services are all related to diagnostic tests for hereditary diseases.  More 
and more DNA markers for diseases are being found as a result of the Human Genome 
Project.  Because of Medical Services Commission rules on genetic testing, no predictive 
tests are performed, only diagnostic tests.  These tests show definitively that a patient 
does or does not have a specific genetic abnormality directly associated with a disease. 
MGL is expanding their menu of services as the result of the approval of Dr. 
Casey’s Toward a Sustainable Approach to Rare Genetic Disease Testing in British 
Columbia: Final Business Case for Clinical Services39 in June 2008.  The detailed 
examination of MGL services will look at pre-approval tests, post-approval tests, and 
speculative tests for the future. 
4.2.1 Current 
MGL offers 43 distinct genetic tests40, including: 
• Charcot-Marie-Tooth — hereditary neuropathy 
                                                
39 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services. 
40 See Appendix B: C&W Molecular Genetics Test Menu on page 63 for the complete menu 
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• Connexin 26 — deafness 
• Cystic Fibrosis — lung tissue & small intestine mucosal disease  
• Fragile X — inherited mental retardation 
• Haemoglobin S, C — blood disorders 
• Haemophilia A — blood clotting disorder 
• Thalassemia α and β — anaemia 
• X-Linked Ichthyosis — STS Deficiency 
In fiscal 2006/7, MGL tested more than 4000 samples.  Estimated growth for 
fiscal 2007/8 is over 20% to more than 5000 samples.  With the tests added in June 2008, 
projected demand in fiscal 2008/9 is estimated at approximately 7500 samples. 
4.2.2 Possible Future 
MGL has already proposed developing new tests “in demand by the B.C. 
healthcare community but presently unavailable in the province”.41 The proposal was 
approved in June 2008 to add 10 additional tests42 including: 
• Craniosynostosis syndromes — skull deformation 
• Hereditary hemorrhagic telangiectasia (HHT) — malformation of blood vessels 
• Long QT syndrome (LQTS) — cardiac rhythm disorder 
• Marfan syndrome — connective tissue disorder 
• Neurofibromatosis Type 1 and 2 — fibroid tumors on nerves 
All future services are speculative.  Those proposed by MGL are less speculative 
than others.  Other possible future tests are representative placeholders — that is, testing 
may be done for these conditions or others of roughly similar prevalence.  I present 
scenarios for comparison, using these and other potential tests as guides for market size 
                                                
41 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services, pg 5 
42 See Appendix F: June 2008 Tests to be Added on page 70 for a complete list. 
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and demand estimation43.  It is not likely that any specific predicted scenario will be 
correct, because genomic medicine and pharmacogenomics are fast moving fields. 
Other potential tests include BRCA1 and 2, but testing is already available in 
province from the B.C. Cancer Agency.44  As more diseases are linked to genetic 
markers, testing demand is likely to rise.  Recent publications suggest genetic links in the 
following conditions: 
• Alzheimer's disease45 — common form of dementia 
• Crohn’s disease46 — autoimmune gastric disorder 
• Sporadic amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease)47 — 
neurodegenerative disease 
More speculative genomic medicine tests include: 
• Detection of patients susceptible to adverse drug reactions48 — including 
Cytochrome P-450 testing for drug metabolizing variations. 
• Detection of autoimmune susceptibility markers — including HLA-DRB1 testing. 
• Identifying so-called “responders” — finding genetic markers for those in trials or 
treatment who benefit from a drug.49 
                                                
43 See Section 4.5, Detailed Examination of Demand on page 37 for demand scenarios. 
44 B.C. Cancer Agency. (2005). Genetic Counselling and Testing. Retrieved 2008.07.04, 
http://www.bccancer.bc.ca/PPI/Prevention/Hereditary/Geneticcounsellingandtesting.htm#testing 
45 Paddock, C. (2008). Scientists Find New Gene Link To Alzheimer's Disease. Retrieved 2008.07.04, 
http://www.medicalnewstoday.com/articles/112803.php; and Marambaud, P., Dreses-Werringloer, U., 
Lambert, J.-C., Vingtdeux, V., Zhao, H., Vias, H. et al. (2008). A Polymorphism in CALHM1 Influences 
Ca2+ Homeostatis, Aβ Levels, and Alzheimer's Disease Risk. Cell, 133, 1149-1161 
46 Henderson, M. (2008). Gene discovery will help to fight Crohn's disease. Retrieved 2008.07.04, 
http://www.timesonline.co.uk/tol/news/uk/science/article4238020.ece 
47 Science Daily. (2008). New Gene Responsible For Lou Gehrig's Disease Identified. Retrieved 
2008.07.04, http://www.sciencedaily.com/releases/2008/03/080331122528.htm 
48 Daly, A. K., King, B. P., & Leathart, J. B. S. (2005). Cytochrome P450 Protocols (320). Secaucus, NJ: 
Springer Science & Business Media; and Ingelman-Sundberg, M. (2001). Implications of Polymorphic 
Cytochrome P450-Dependent Drug Metabolism For Drug Development. Drug Metabolism and 
Disposition, 29(4), 570-573; and Ingelman-Sundberg, M. (2008). Pharmacogenomic Biomarkers for 
Prediction of Severe Adverse Drug Reactions. New England Journal of Medicine, 358;6 
49 Connor, S. (2003). Glaxo chief: Our drugs do not work on most patients. Retrieved 2008.07.04 
  27 
These two previous categories all fail my Criterion 1: these tests are predictive 
rather than diagnostic.  However, they serve as quantitative examples of the kind of test 
that might be added in the future. 
DNA based testing can also affect treatment choice when used to conclusively 
identify disease-causing organisms including: 
• Babesia microti and WA1 (babesiosis)50 
• Bordetella pertussis (pertussis or whooping cough)51  
• Borrelia burgdorferi (chronic Lyme disease)52 
• Ehrlichia chaffeensis (human monocytic ehrlichiosis or HME)53 
• Ehrlichia phagocytophilia (human granulocytic ehrlichiosis or HGE)54 
• Mycobacterium55 
• Mycoplasma incognitus56 and pneumoniae57 
As more genetic markers are discovered for more medical conditions (hereditary, 
epigenetic, and infectious) the field of potential tests becomes larger.  Should genomic 
medicine become a reality, full genome sequencing will become commonplace.58 
                                                
50 IGeneX, Inc. Babesiosis. Retrieved 2008.07.04, http://www.igenex.com/tickset1.htm 
51 Division of Health Surveillance - Epidemiology. (2007). Pertussis PCR testing at the Vermont 
Department of Health Laboratory. Infectious Disease Bulletin Retrieved 2008.07.04, 
http://healthvermont.gov/pubs/IDB/documents/IDB12_07.pdf; and Kirchner, J. T. (1999). Infectious 
Cause of Chronic Cough in Adults. American Family Physician. 
52 IGeneX, Inc. Detection of Borrelia Burgdorferi by PCR -- Overview. Retrieved 2008.07.04, 
http://www.igenex.com/lymeset5.htm 
53 IGeneX, Inc. Ehrlichiosis. Retrieved 2008.07.04, http://www.igenex.com/tickset2.htm 
54 IGeneX, Inc. Ehrlichiosis. Retrieved 2008.07.04, http://www.igenex.com/tickset2.htm 
55 MacReady, N. (2006). PCR Test Hastens Identification of Mycobacteria Species. Retrieved 2008.07.04, 
http://www.medscape.com/viewarticle/546427 
56 Vojdani, A. & Choppa, P. C. Sensitive Method for the Quantitative Detection of Mycoplasma Infections. 
Retrieved 2008.07.04, http://www.immuno-sci-lab.com/html/pcr.html 
57 Kempsell, K. E., Cox, C. J., McColm, A. A., Bagshaw, J. A., Reece, R., Veale, D. J. et al. (2001). 
Detection of Mycobacterium tuberculosis Group Organisms in Human and Mouse Joint Tissue by 
Reverse Transcriptase PCR: Prevalence in Diseased Synovial Tissue Suggests Lack of Specific 
Association with Rheumatoid Arthritis. Infection and Immunity, 69(3), 1821 - 1831 
58 This is perhaps a reversal of the causative statement: if full genome sequencing becomes cost effective 
(and therefore commonplace), genomic medicine will become a reality. 
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4.3 Detailed Examination of Funding 2007-2008 
Table 3 provides basic financial information for MGL’s fiscal 2007/8.59  
Referred-in revenue comes from tests referred to MGL from outside the B.C. healthcare 
system — the inverse of OOC payments.  Compensation refers to total labour costs 
(excluding the Director).  Supplies provides for chemical reagents, laboratory 
consumables, and maintenance contracts. 
  2007-2008 Budget   2007-2008 Actual  
   Expenses   Revenue   Totals   Expenses   Revenue   Totals  
 Referred-In 
Revenue 
   $25,000       $93,297    
 Total Revenue      $25,000      $93,297  
 Compensation   $(399,726)     $(363,038)    
 Supplies   $(99,624)     $(213,908)    
 Total Expenses       $(499,350)      $(576,946) 
 Budget Total      $(474,350)     $(483,649) 
Table 3: 2007-2008 MGL Budget vs. 2007-2008 MGL Expenditures 
4.3.1 Funding Sources 
Ninety-five percent of MGL’s budget in 2007-2008 came from C&W funding, 
with the remaining five percent budgeted as referred-in revenue.  As budgeted, C&W 
funding is divided 80% for Compensation and 20% for Supplies.  As shown in the right 
half of Table 3, the actual division of money between salaries and supplies is closer to 
65%-35% than 80%-20%.  The differential comes largely from increasing referred-in 
revenue and using that revenue for supplies.  A small diversion of funds from 
compensation (via an unfilled .5 FTE position) makes up most of the difference. 
                                                
59 Casey, B. (2008). 07‐08 Genetics Fiscal Position.xls 
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4.3.2 Cost Sources 
MGL’s continuing costs come from two primary sources: 
• Employee salaries 
• Supply funding 
A third, minor, source of costs is maintenance agreements on equipment, but cost 
tracking at the laboratory level does not appear to capture this as a separate category.  For 
fiscal 2007/8, maintenance agreements are estimated at $25K60.   
4.3.2.1 Employee Salaries 
Labour expense is by far MGL’s most significant cost source.  Step increases and 
reclassification cause labour expenses to rise annually, regardless of test volume. 
MGL currently has 3.5 FTE technologists, soon to expand to 5 FTE technologists.  
The Director’s salary is not included in MGL’s global budget from C&W. 
Labour costs are now 63% of MGL’s costs. 
4.3.2.2 Supply funding 
Funding for reagents and other laboratory consumables is the most variable of 
MGL’s budget categories.  Over the fiscal years from 2004/5 to 2007/8, real budgeted 
supply funding has dropped precipitously from nearly $90K to about $25K61, more than a 
70% reduction.  During that same period, samples tested have risen over 45%.  In 2007/8, 
supply funding rose back to $100K, which was still insufficient to cover necessary costs 
                                                
60 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: Final Business Case for Clinical Services 
61 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services. 
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of nearly $215K62.  The difference between $99K budgeted supply costs and the actual 
$214K supply expense can be accounted for by: 
• $99K in referred-in revenue applied to the purchase of supplies 
• Repurposing of other funds, including funding for an unfilled .5 FTE position 
According to budget, the mean supply cost per test performed was budgeted to 
drop from $25 to $5 in five years. The mean supply cost reduction is almost certainly an 
accounting anomaly rather than a real reduction.  However, 2008 actual expense figures 
show a mean supply cost per test of $42, 167% of the 2004 budgeted supply cost per test. 
So at a time when the supply budget was fixed, the number of tests increased and the 
mean per test cost also increased.  Supply funding is 37% of MGL’s costs. 
4.3.2.3 Potential Future Technology Costs 
MGL has no plans to upgrade equipment beyond that authorized by the 2008 
funding change.  According to Dr. Casey, the PHSA lab organization is currently 
discussing outsourcing DNA sequencing to the Genome Sequencing Centre.  If 
implemented, this transfer of responsibility would “…cut [MGL’s] costs dramatically and 
obviate the necessity of upgrading [MGL’s] sequencing instrument(s)…”63.  
                                                
62 Casey, B. (2008). 07-08 Genetics Fiscal Position.xls. 
63 Casey, B. (2008). Re: [Sustainable Funding Analysis] Collected Questions 
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4.3.3 Current Shortfall 
 
Figure 2: Supply Budget vs. Demand64 
In fiscal 2008, MGL had a supply budget shortfall (compared to actual expenses) 
of $115K.  MGL has successfully increased samples processed despite declining real 
supply budgets.  By increasing efficiencies, repurposing funds, and increasing referred-in 
revenue from out-of-province tests, MGL has managed to maintain accelerating growth 
in test volumes.  
Despite increased operational efficiency, MGL planned to send 400 samples out 
of country (OOC) for testing at a total cost of $300K ($750 per test mean cost) because of 
lack of capacity or lack of a required test. 
                                                
64 Graph from Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British 
Columbia: Final Business Case for Clinical Services 
  32 
4.4 Alternative Funding Strategies 
Current funding models within the B.C. Ministry of Health include global funding 
(as MGL is currently funded) and per-test funding (as MSP compensates private blood 
labs and out-of-province genetic test labs).  Ownership can be public (e.g. MGL) or 
private (e.g. BC Biomedical Laboratories, Ltd.65).  Combining forms of funding and 
ownership presents a short menu of possible funding strategies: 
• Globally funding MGL as a publicly owned lab (current); 
• Per-test funding MGL as a publicly owned lab; 
• Fixed cost (global equivalent) funding a privately owned lab — can be discounted 
as unrealistic.  No private corporation is likely to accept such an arrangement 
where more volume doesn’t bring more income; 
• Per-test funding MGL, Inc. as a privately owned lab (privatizing MGL); 
• Per-test funding genetic tests through existing labs (outsourcing). 
4.4.1 Current Global Funding for MGL as a Public Lab 
MGL is currently funded as global funding from the Children’s & Women’s 
Health Centre of British Columbia (C&W), meaning that MGL receives a fixed annual 
budget from the C&W annual budget.  In recent years, the MGL budget has been 
constant.  Because of rising personnel costs, the available non-labour budget has 
decreased. 
The B.C. Medical Services Plan pays for outsourced samples according to MSP’s 
Out-of-Country Medical Care Guidelines.66  These costs are not (technically) part of the 
                                                
65 http://www.bcbio.com/ 
66 Medical Services Commission. (2006). Medical Services Commission Out of Province and Out of Country Medical Care Guidelines for Funding Approval. Retrieved 2008.07.05, http://www.health.gov.bc.ca/msp/infoben/ooc_funding_guidelines.pdf 
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MGL’s budget but do represent real costs to the provincial Ministry of Health for genetic 
testing. 
In 2007, Dr. Brett Casey proposed Toward a Sustainable Approach to Rare 
Genetic Disease Testing in British Columbia: Final Business Case for Clinical 
Services.67  In June 2008 the proposed budget increase was approved.  This increased 
MGL’s annual budget by $240K (to approximately $800K) and allocated a one-time 
investment of $350K for equipment.  The purpose of this increase is to facilitate testing 
for Long QT Syndrome (LQTS) and other new tests.68  This funding scenario maintains 
the current global funding model as modified in June 2008, and mirrors the provincial 
funding model for in-hospital laboratories. 
4.4.2 Test-Based Funding MGL as a Public Lab 
The B.C. Ministry of Health pays privately owned laboratories in B.C. on a per-
test basis through the Medical Services Plan.  The market price of a privately performed 
blood test, therefore, includes fixed costs as well as variable costs, and profit for the 
private laboratory. 
4.4.2.1 Pure Per-Test Funding 
Payments to MGL could be handled just as are payments to privately owned 
laboratories.  On a total cost basis, the aggregate of per-test payments would roughly 
equal MGL’s total budget as adjusted for test volume.  For 2007/8, original budgeted cost 
per test would be roughly $115 (total budget of $577K divided by 5100 tests performed).  
                                                
67 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services 
68 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services 
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As modified in June 2008, cost per test would be roughly $160 (total budget of $817K 
divided by 5100 tests performed). 
4.4.2.2 Mixed Per-Test Funding 
MGL’s budget could be split into fixed and semi-variable costs (salaries, 
facilities, maintenance contracts) and variable costs (reagents, other consumables, courier 
service, and postage).  For fiscal 2007/8 as originally budgeted, semi-variable costs 
would be $363K and variable costs would be $214K or $42 per test up to the volume 
manageable by the current staff.  The breakdown for fiscal 2008/9 as modified is 
unavailable until hiring is complete and salaries are established.  An estimated 
breakdown for 2008/9 as modified in June might be semi-variable costs of $600K and 
variable costs of $215K.  Semi-variable costs would rise according to step increases and 
promotions and staff additions69, while variable costs would rise and fall according to the 
number and cost of tests performed and developed. 
4.4.3 Privatization (Test-Based Funding of MGL, Inc. as a Private Lab) 
Taking the MGL from public ownership (aka MGL) to private ownership (aka 
MGL, Inc.) and contracting with the resulting company to perform genetic testing at 
market rates.  This funding scenario extends the current provincial model for other 
medical testing outside hospital laboratories, such as blood testing and radiology, to 
genetic testing.  MGL, Inc. is free to offer services to other clients throughout the world, 
just as existing private laboratories do. 
                                                
69 Salaries are a semi-variable cost — fixed over a wide range of volume, and then increasing/decreasing by 
a relatively large increment as one or more FTEs are hired/laid off. 
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4.4.4 Outsourcing 
Closing the MGL and using outside laboratories exclusively for genetic testing at 
market rates.  This funding scenario relies entirely upon market forces for genetic testing. 
4.4.5 Other Potential Sources of Revenue 
MGL has two potential future sources of revenue: referred-in testing and licensing 
of established tests.  MGL made over $90K through referred-in testing in fiscal 2007/8 
and there is every reason to believe that revenue stream can increase if MGL has 
additional capacity.  Tests are not yet being licensed, but any test developed at MGL 
could be licensed to other laboratories for additional revenue. 
4.4.5.1 Tests for non-MSP clients 
MGL could offer tests on the open market if they have excess testing capacity.  
MGL has spent as much as $5400 per test.70  Other laboratories list test prices from $200 
to $6000. The mean price of a test from Molecular Diagnostics Laboratories (MDL)71, 
GeneDX72, Massachusetts General73, Johns Hopkins74, and Tulane75 is $880/test, with 
averages at the various laboratories ranging from $352/test at MDL to $1472/test at 
Tulane.76 
                                                
70 Casey, B. (2008). Re: [Sustainable Funding Analysis] Collected Questions, pg 5. 
71 Fontaine, R. N. (2008). Customer Prices and CPT Codes 2006 
72 GeneDX. (2008). Current Price List. Retrieved 2008.07.14, 
http://www.genedx.com/pdf_files/current_price_list.pdf 
73 Massachusetts General Hospital. Neurogenetics DNA Diagnostic Laboratory Price List. Retrieved 
2008.07.13, http://www.massgeneral.org/neuroDNAlab/price_list2_4-04.xls 
74 Johns Hopkins DNA Diagnostic Laboratory. Search for Tests by Syndrome Name. Retrieved 2008.07.14, 
http://www.hopkinsmedicine.org/dnadiagnostic/SyndromeSearch.htm 
75 Tulane Health Sciences Center. Matrix DNA Diagnostics. Retrieved 2008.07.11, 
http://www.som.tulane.edu/gene_therapy/matrix/matrix_dna_diagnostics.shtml 
76 Means calculated without access to frequency of tests. 
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Because tests from the open market will provide more revenue per test than B.C. 
internal testing, safeguards must be put in place to guarantee that internal tests have 
absolute priority over non-MSP tests.  Additional revenue from non-MSP tests can be 
returned to the province as income, set aside for capacity expansion, or used for some 
other purpose as decided by the Ministry of Health. 
4.4.5.2 Test Licensing 
Upon developing useful tests, even if not unique, MGL could license those tests 
to other laboratories.  Licensing fees are likely to be low, because tests are developed 
from publicly available (and unprotect-able77) information linking specific DNA 
locations and disease. 
4.4.6 Summary 
Table 4 shows summary information for each funding option, including whether 
costs are fixed or vary by volume, the funding agencies, existing organizations using the 
funding model, how the model scales up and down, whether the lab ownership is public 
or private, and whether the model is sustainable and affordable.  Much of this information 
applies directly to the business criteria 4 – 6 on page 21.  I will use it in combination with 
other data to form my recommendations. 
                                                
77 Wright, C. (2008). European recommendations on patenting and licensing genetic tests. Retrieved 
2008.07.25, http://www.phgfoundation.org/news/4140/.  Although this information is technically a 
“discovery” and not an invention, patents have been granted.  Some jurisdictions choose to ignore these 
patents and allow use of the discovered information.  This issue will eventually be litigated in both 
national and international courts. 
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Characteristics 
Current 
Global 
Funding 
Per-Test 
Funding 
Privatization Outsourcing 
Fixed Costs X    
Cost Varies by Volume  X X X 
Funding Agency (-ies) C&W + 
MSP 
MSP;  
C&W + MSP 
MSP MSP 
Organizations in B.C.’s health 
system using this funding 
model 
Hospital 
Labs 
Private Labs; 
None 
Private Labs Private Labs 
Scales up Poorly Well Very well Very well 
Scales down Adequately Adequately Very well Very well 
Public/Private Ownership Public Public Private Private 
Sustainable? No Yes Yes Yes 
Affordable? Yes Volume 
Dependent 
Volume 
Dependent 
Volume 
Dependent 
Table 4: Summary of Funding Options 
4.5 Detailed Examination of Demand 
MGL’s primary potential market is the population of B.C.  But that market is only 
reached if the Ministry of Health moves to fully genomic medicine.  At present, MGL’s 
end-user market is clinicians with: 
• Patients at risk of hereditary disease 
• Patients requiring diagnosis of syndromes where the differential diagnosis 
includes hereditary diseases 
MGL directly serves only that portion of the market requiring tests MGL 
provides, while facilitating application by clinicians to the MSP OOC program to have 
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samples sent to out-of-province labs for testing78.  MGL also hands some patients to other 
in-province laboratories79. 
 
 
Figure 3: Comparison of Samples Processed Inside and Outside B.C.80 
MGL has three ways to expand the market: 
• Test at a higher rate 
• Offer more tests 
• Offer tests to a larger population 
Since genetic disease prevalence is at least roughly known, I will estimate the 
number of likely cases (LCs) of each genetic disease based upon the B.C. population81.  I 
                                                
78 This diversion of effort to paperwork for OOC samples represents a dead weight monetary loss to MGL 
and confirms that patient care is their primary driver.  Consolidating genetic testing within the province 
and the management of OOC genetic testing into a single office will convert the dead weight loss to a 
cost of OOC testing, which is how it should be tracked. 
79 See Appendix C: C&W Cytogenetics Test Menu through Appendix E: C&W Biochemical Genetics Test 
Menu starting on page 63 for lists of tests provided by other C&W laboratories 
80 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services. 
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can estimate the number of tests MGL performs per likely case, allowing me to model 
demand based upon tests offered, the prevalence of those diseases, and the size of the 
target (market) population. 
The rate of testing per 1000 LCs is 279 - 444 tests per 1000 LC or 28% to 44%, as 
shown in Table 5, below.  Roughly speaking, each LC results in between ¼ and ½ of a 
genetic test at MGL.  Without better information on the number of pre-natal tests, it’s 
hard to estimate how many of these tests are confirming a diagnosis already made 
through other means, but .25 - .50 tests per LC seem low for effective coverage in the 
post-natal population.  A change to 2 tests per LC would increase the within-B.C. market 
by between four and eight times.  See Table 5 for estimates of testing volume at double 
the existing rate and at a rate of one test per LC. 
Offering tests for additional genetic problems as a market expansion is already 
under way.  The additional budget added in June 2008 addresses a proposal to add ten 
new tests to the 43 currently offered, increasing the test menu by 23% and the likely 
number of cases in B.C. by between 43% and 48%. 
Offering tests throughout Canada or the US provides MGL with substantially 
larger markets.  However, it’s unclear what portion of those markets is underserved, and 
MGL might simply be entering a satisfied and competitive market.  Competitive 
laboratory rates of testing and number of tests are not available. 
 
                                                                                                                                            
81 See Appendix A: Prevalence of Genetic Diseases on page 60 for more information on the prevalence of 
genetic diseases. 
  40 
  Low LC 
Estimate  
 High LC 
Estimate  
Tests Performed in B.C.  5,10082   5,10082  
LCs (old tests) by known prevalence  5,343   8,506  
known prevalence covers what % of tests? 47% 47% 
LCs (old tests) estimate  11,488   18,289  
Tests/1000 LCs  444   279  
LCs (added tests) by known prevalence  5,567   7,855  
Total LCs  17,055   26,143  
% Increase in LCs with added tests 48% 43% 
Projected Tests Performed with Added Tests  7,571   7,290  
  Low LC 
Estimate  
 High LC 
Estimate  
Projected Tests (Existing Tests in BC)  5,10082   5,10082  
Projected Tests (Added Tests in BC)  7,571   7,290  
Projected Tests at 2x Test Rate (Existing Tests in BC)  10,200   10,200  
Projected Tests at 2x Test Rate (Existing + Added Tests 
in BC) 
 15,143   14,581  
Projected Tests at 1 Test/LC (Existing Tests in BC)  11,488   18,289  
Projected Tests at 1 Test/LC (Existing + Added Tests in 
BC) 
 17,055   26,143  
%Increase in Tests at 1 Test/LC (All Tests in BC) 334% 513% 
Table 5: Projected Test Volume with proposed added tests, June 2008 and at higher test rates 
4.5.1 B.C. Consumers 
B.C.’s present population of between 4 and 4.4 million people supported between 
3500 and 5500 tests in the years 2004 – 2008.  Precise information on the number of tests 
referred-in is unavailable, but $93K in referred-in revenue suggests anywhere from 46 to 
175 tests are from out-of-province.83 
                                                
82 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: Final Business Case for Clinical Services. 
83 $93K referred-in revenue divided by $526 (the lowest average price of a genetic test from the available 
test menus from outside laboratories) = 176 tests. 
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By researching the known prevalence of diseases84 diagnosed by the existing 
tests, I estimate the number of Likely Cases (LCs) in B.C. in Table 5.  Combined with the 
percentage of actual tests performed and the percentage of tests for which I have LCs, I 
obtain a ratio of tests done in B.C. per 1000 LCs. 
Adding the LCs for the added tests provides a total number of LCs in B.C. and re-
applying the ratio of tests done per 1000 LCs yields a projected number of tests that will 
be performed annually once the new tests are added to the menu.  In addition, I provide 
estimates of the projected numbers of tests if the testing rate should increase, which 
might occur if MGL’s services were more widely or forcefully presented to clinicians. 
4.5.2 Out of Province Consumers 
Using the same Tests/LC value as in B.C., projections for the potential number of 
tests to be performed in Canada and the US are: 
Out of BC Demand  Canada 
Low  
 Canada 
High  
 US Low   US High  
LCs (old tests)  86,188   137,209   782,458   1,245,644  
LCs (added tests)  41,765   58,931   379,208   535,046  
Total LCs  127,953   196,139   1,161,667   1,780,690  
Total LCs/1000 * Tests/1000 LCs  56,804   54,696   515,710   496,569  
Table 6: Projected Test Demand outside B.C. 
Out of BC Demand  Canada 
Low  
 Canada 
High  
 US Low   US High  
Projected Tests at 1 Test/LC 
(Existing Tests) 
 86,188   137,209   782,458   1,245,644  
Projected Tests at 1 Test/LC 
(Existing + Added Tests) 
 127,953   196,139   1,161,667   1,780,690  
Table 7: Projected Test Demand outside B.C. at higher testing rates 
                                                
84 See A: Prevalence of Genetic Diseases on page 60 for the prevalence of some genetic diseases. 
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5 COMPARISON OF FUNDING ALTERNATIVES & 
OUTCOMES 
In order to determine the preferred funding strategy, I examine scenarios for test 
volume, testing rate, and test cost.  Volume scenarios include linear and exponential 
projections based upon previous years actual test data.  Testing rate scenarios include the 
addition of tests approved in June 2008 and more speculative scenarios including the 
addition of a widespread (15% of the population) test roughly equivalent to the CYP2D6 
drug metabolism test and the adoption of widespread genome sequencing.  Test cost 
projections are made based upon actual costs within the MGL, costs to the province in the 
OOC program, and average test costs published by other genetic testing laboratories. 
By comparing the expected number of tests and the expected costs of tests in 
various scenarios, I can apply my business criteria 4 – 6 from Section 4.1.1.1 on page 21 
to establish which funding strategy is preferred.  
5.1 Assumptions 
Testing rates are constant across B.C., Canada, and the US. 
Drug metabolizing rate tests will take place at the same relative rate as other 
hereditary disease tests. 
Fifteen percent of consumers will request full genome sequencing.  This includes 
those who have reason to believe they suffer from a hereditary genetic disease and those 
who may believe they have a metabolizing rate defect.  Fifteen percent is the bottom end 
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of the lowest range of testing interest among women surveyed concerning breast cancer 
testing.85  Many people at risk for genetic disorders do not choose to be tested.86 
Privatized and outsourced funding methods merge together because a private 
MGL, Inc. will either expand to become a significant player in the genetic testing market 
(and will thus enjoy larger markets, access to capital, and economies of scale) or MGL, 
Inc. will be acquired by a major player in the genetic testing market (and will thus enjoy 
larger markets, access to capital, and economies of scale).  Collectively the privatized and 
outsourced funding models may thus be referred to as privately owned. 
5.1.1 Test Volume Projections 
Table 8, below, shows various scenarios for test volume based upon historical and 
projected levels.  All scenarios begin with actual values for 2007 and 2008 with projected 
values for 2009 based upon 2008 volume plus the planned added tests.  From 2010 on, all 
values are projected either linearly (based upon 2007 – 2008 growth or 2008 – 2009 
growth) or exponentially (based upon a flat 10% growth rate, the 2007 – 2008 volume 
ratio or the 2008 – 2009 volume ratio). 
Scenarios show five-year testing volume should range between 11,000 and 35,000 
samples, or between 2x and 7x current test volume. 
                                                
85 Bottorff, Joan L., Ratner, Pamela A., Balneaves, Lynda G., Richardson, Chris G., McCullum, Mary, 
Hack, Tom et al. (2002). Women's Interest in Genetic Testing for Breast Cancer Risk: The Influence of 
Sociodemographics and Knowledge. Cancer Epidemiology, Biomarkers & Prevention, 11, 89-95., pg 5. 
86 Quaid, K. A. & Morris, M. (1993). Reluctance to undergo predictive testing: the case of Huntington 
disease. American Journal of Medical Genetics, 45(1), 41 - 45; and van der Steenstraten, I. M., Tibben, 
A., Roos, R. A. C., van de Kamp, J. J. P., & Niermeijer, M. F. (1994). Predictive Testing for Huntington 
Disease: Nonparticipants Compared with Participants in the Dutch Program. American Journal of Human 
Genetics, 55, 618 - 625. 
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  Linear Test Growth   Exponential Test Growth  
 Year   07/08 
diff  
 08/09 
diff  
10%  07/08 
ratio  
 08/09 ratio  
2007  4,05087   4,05087   4,05087   4,05087  4,05087  
2008  5,10087   5,10087   5,10087   5,10087   5,10087  
2009  7,500   7,500   7,500   7,500   7,500  
2010  8,550   9,900   8,250   9,444   11,029  
2011  9,600   12,300   9,075   11,893   16,220  
2012  10,650   14,700   9,983   14,976   23,853  
2013  11,700   17,100   10,981   18,859   35,077  
      
 growth   1,050   2,400  110% 126% 147% 
Table 8: Projected Test Volumes (various scenarios) 
5.1.2 Testing Rate Growth 
Cases for Testing Rate Growth (TRG) include: 
• B.C. population growth 
• New market growth (assumes provision of for-profit testing outside B.C.) 
Testing growth much higher than population growth requires that either currently 
tested syndromes become more prevalent (unlikely) or that doctors increase their testing 
frequency for current tests. 
New market growth requires expansion into non-B.C. markets or the development 
of new tests. Table 6 and Table 7 in Section 4.5.2 on page 41, show potential market 
sizes for existing tests in Canada and the United States at various testing rates.  The 
market potential of Canada and the United States is between 7.5x and 68x B.C. at current 
testing rates and as much as 250x current B.C. at higher testing rates. 
                                                
87 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: Final Business Case for Clinical Services. 
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5.1.3 Test Type Growth 
Cases for Test Type Growth (TTG) include: 
• Addition of proposed tests 
• Addition of a CYP2D6 drug metabolizing test 
• Addition of full genome sequencing 
 Proposed Tests CYP2D6 Full Genome 
B.C. Only Demand growth is 
projected at an 
immediate 45%. 
Future growth is at 
population growth rate 
Potential 7x demand 
growth 
Potential 3.5x – 55x 
demand growth for full 
genome sequence 
New Markets Market expands 7.5x 
(Canada) or 68x (US) 
Market expands 5.5x – 
220x (Canada) or 500x 
– 2000x (US) 
Market expands 29x – 
430x (Canada) or 260x 
– 3900x (US) 
Table 9: Demand / Market Growth for Representative New Genetic Tests 
5.1.4 Test Prices 
Prices vary widely by test and laboratory, largely due to degree of test complexity 
(number of exons per gene and variations possible) and automation (capital investment in 
laboratory equipment).  Good information on the frequency of various tests is not 
available.  Five laboratories (Molecular Diagnostics Laboratories88, GeneDX89, 
Massachusetts General90, Johns Hopkins91, and Tulane92) publish price lists, suggesting a 
mean market price for the average genetic test at $880. 
                                                
88 Fontaine, R. N. (2008). Customer Prices and CPT Codes 2006 
89 GeneDX. (2008). Current Price List. Retrieved 2008.07.14, http://www.genedx.com/pdf_files/current_price_list.pdf 
90 Massachusetts General Hospital. Neurogenetics DNA Diagnostic Laboratory Price List. Retrieved 2008.07.13, http://www.massgeneral.org/neuroDNAlab/price_list2_4‐04.xls 
91 Johns Hopkins DNA Diagnostic Laboratory. Search for Tests by Syndrome Name. Retrieved 
2008.07.14, http://www.hopkinsmedicine.org/dnadiagnostic/SyndromeSearch.htm 
92 Tulane Health Sciences Center, Matrix DNA Diagnostics 
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Lab Mean Price 
MDL $352 
GeneDX $1,420 
Mass General $525 
Johns Hopkins $626 
Tulane $1,472 
Overall $879 
2008 Actual Cost $750 
Actual / Mean 85% 
Table 10: Mean Test Price 
5.2 Current and Future Test Costs by Funding Method 
Cost to the Ministry of Health for the average genetic test done at MGL (while 
publicly owned) is $179, including fixed and variable costs as well as the five-year 
amortized cost of the new equipment budgeted of $18/test93.  Estimated cost to the 
Ministry of Health of the average genetic test done on the public market is $879 
compared with actual 2008 cost of $750/test (85% of the mean cost).  The lowest price of 
any genetic test on the public market is $231, more than 25% higher than the mean cost 
per test at MGL. 
Funding Method   Cost/Test   New Equipment   Total  
 Current  $160  $18  $179  
 Per-Test  $160  $18  $179  
 Privately Owned (Average)  $879  $0  $879  
 Privately Owned (Adjusted)  $750  $0  $750 
 Privately Owned (Minimum)  $231  $0  $231  
Table 11: Current Test Costs by Funding Method 
                                                
93 Assuming 6% interest over five years, $350K has a future value of $468K or almost $94K/year, divided 
among 5,100 tests/year = $18. 
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Because genetic testing and genomics are so fast changing, I expect that costs will 
change over time.  Economies of scale will benefit privately owned funding methods 
more than publicly owned methods.  Future prices and costs are speculative, so several 
cases are provided as a sensitivity analysis. 
Scale economies without major technological change may reduce the price of 
testing to half or even one-quarter at agencies that can take advantage of them (privately 
owned funding models or public funding on a per-test basis).  Because future test 
requirements (number of genes and exons) and equipment capability (level of automation 
for handling samples, automatic extraction of DNA) and price are not entirely 
predictable, rough scenarios must suffice.  If demand were to grow by 10x, a linearly 
projected investment of up to $5 million would add a maximum of $27 to the cost of each 
test94.  If demand were to grow by 100x or more, an exponential equipment investment in 
automation of up to $100 million would add a maximum of $53 to the cost of each test95.  
These numbers are illustrative only because machine capability and cost are changing 
rapidly and future test specifics are, as yet, unknown.  If full-genome sequencing 
becomes cost-viable at $1000, individual tests after sequencing have a marginal cost 
approaching $0.96 
                                                
94 Assuming 6% interest over five years, $5M has a future value of $6.7M or $1.3M/year, divided among 
51,000 tests/year = $27.  This is a sensitivity analysis, not a prediction that handing 10x the samples 
would require a $5 million capital increase. 
95 Assuming 6% interest over five years, $100M has a future value of $134M or $27M/year, divided among 
510,000 tests/year = $53. This is a sensitivity analysis, not a prediction that handing 100x the samples 
would require a $100 million capital increase. 
96 Because once the genome sequence is stored, further testing consists of electronically searching data 
instead of extracting and sequencing DNA. 
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Funding   Scale Econ.   Huge Scale 
Econ.  
 10x demand   100x 
demand  
 Current   X   X   X   X  
 Per-Test  $80 $40 $66 $93 
 Privately Owned  $440 $220 $27 $27 
Table 12: Potential Future Test Costs by Funding Method and Scenario 
Current funding methods (hospital global funding plus MSP OOC funding) do not 
allow for the current annual rate of test growth.  They are completely inadequate for the 
level of expansion required to achieve large economies of scale or to make the potential 
investments necessary to handle 10x or 100x demand growth.  Per-test funding methods 
allow for the smaller economies of scale and suggest that costs will drop over time until a 
very large investment in equipment is required to meet demand.  However, publicly 
funded laboratories face difficulty obtaining capital for larger investments necessary to 
manage very large demand increases.  Privately owned labs have the advantages of per-
test funding as well as an advantage in making large investments because of their access 
to capital and the larger markets they serve. However, the higher cost per test of private 
labs makes them considerably less affordable than MGL while demand is relatively low. 
 
 
Characteristics 
Current 
Global 
Funding 
Per-Test 
Funding 
Privatization Outsourcing 
Sustainable? No Yes Yes Yes 
Affordable? $180/test 
More 
$180/test 
More 
$750/test 
Less 
$750/test 
Less 
Table 13: Funding Models Sustainability and Affordability with Current Test Price Information 
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5.3 Projected Costs by Funding Method 
Figure 4, Table 14, and Table 15 show projected cost ranges over five years by 
funding scenario.  If the best-case private funding scenario (assuming 10x demand and 
attendant cost reductions to $48/test) is correct, it minimizes total five-year costs at 
$2.6M – $5M.  That scenario is highly speculative.  Per-test funding shows the best 
conservative scenario with a total five-year funding range of $10M – $18M and 2013 
annual budget of $2M – $6.25M.   
 
Figure 4: Projected Five-Year Cost Ranges by Funding Scenario 
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   # of Tests  
Total Cost by 
Scenario  
 Low   High   low est.   high est.  Cost/Test  
 Per-Test   $9,809   $18,360   54,938   102,829   $179  
 Private   $48,290   $90,386   54,938   102,829   $750  
 Private (scale)   $24,145   $45,193   54,938   102,829   $374  
 Private (10x)   $2,648   $4,957   54,938   102,829   $48  
Table 14: Total Projected Five-Year Costs by Funding Scenario (costs in $000s)   
  2007 
(actual) 
2008 
(est) 
2009 2010 2011 2012 2013 
low 
est. 4050
97 510097 7500 8250 9075 9983 10981 
# of Tests 
high 
est. 4050
97 510097 7500 11029 16220 23853 35077 
low  $723   $911   $1,339   $1,473   $1,620   $1,782   $1,961  
Per-Test 
high  $723   $911   $1,339   $1,969   $2,896   $4,259   $6,263  
low  $3,026   $3,810   $5,604   $6,164   $6,780   $7,458   $8,204  
Privately 
Owned high  $3,026   $3,810   $5,604   $8,241   $12,119   $17,821   $26,208  
low  $1,513   $1,905   $2,802   $3,082   $3,390   $3,729   $4,102  Privately 
Owned 
(scale 
economies) 
high  $1,513   $1,905   $2,802   $4,120   $6,059   $8,911   $13,104  
low  $195   $246   $362   $398   $438   $481   $529  Privately 
Owned 
(10x 
demand) 
high  $195   $246   $362   $532   $782   $1,150   $1,691  
Table 15: Annual Testing Volume and Estimated Costs by Funding Method (costs in $000s) 
5.4 Summary 
All four funding strategies are sound business practices when properly applied.  
Criterion 4 thus provides no clear guidance for a decision. 
                                                
97 Casey, B. (2007). Toward a Sustainable Approach to Rare Genetic Disease Testing in British Columbia: 
Final Business Case for Clinical Services. 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The funding strategies provide varying degrees of sustainability and affordability.  
Global funding is unsustainable in the long-term because of the increase in demand over 
time and the rapidly changing nature of genetic testing, both technologically and 
medically.  Privatization and outsourcing are currently considerably less affordable than 
per-test funding and seem likely to remain so for the immediate future.  Criterion 5 
selects per-test funding as the most desirable. 
Global funding and per-test funding maintain MGL as a publicly owned 
laboratory, while privatization and outsourcing do not.  Keeping a useful resource in 
public hands better promotes a publicly funded health care system until and unless 
private ownership results in lower costs.  Current costs are lower within the publicly 
owned system and seem likely to remain so until a large change in volume or capital 
investment is required.  The future remains cloudy, but it seems unlikely that the $1000 
genome will arrive in B.C. in the next five years, and so public ownership of MGL 
remains desirable and Criterion 6 selects global or per-test funding. 
Per-test funding thus satisfies all three of the business criteria, while the other 
funding strategies satisfy roughly half (especially if global funding is considered unsound 
because of the rapidly changing nature of the genetic testing field).  Private ownership 
fails primarily on grounds of affordability, and should be re-examined as prices change. 
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Criteria 
Current 
Global 
Funding 
Per-Test 
Funding 
Privatization Outsourcing 
4. Sound Business Practice + (-)98 + + + 
5. Sustainable & Affordable - / + + / + + / - + / - 
6. Public Funding + + - - 
Total (2 or 3) of 4 4 of 4 2 of 4 2 of 4 
Table 16: Funding Strategies and Decision Criteria 
                                                
98 - if global funding is considered unsound business practice because of the rapid rate of change. 
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6 RECOMMENDATIONS 
Recommendations flow from criteria and data.  I have established a list of six 
criteria99 and data on projected test volume and cost according by scenarios and funding 
strategies,100 concluding with Table 16 showing which criteria are met by which funding 
strategy.  Once data and analysis is presented in the right way, questions are answered at 
a glance. 
6.1 Recommended Solution(s) 
According to my business criteria 4 – 6, I am looking for a funding strategy that is 
a sound business practice, sustainable and affordable, and which promotes a publicly 
funded health care system.  The differential between the various strategies is largely and 
most importantly in the areas of sustainability and affordability.  It is by establishing 
which funding strategy is both sustainable and affordable that I find the preferred 
solution.  
6.1.1 Budgeting and Funding 
MGL should be funded by a per-test funding method on the basis of sustainability 
and current affordability along with the long-term benefit to the province of keeping a 
valuable medical resource in public hands.  A per-test funding method balances 
flexibility and lower costs in the near future while maintaining the integrity of the 
publicly funded health system.  When and if substantial ($5M or more) capital investment 
                                                
99 See Section 4.1.1.1 on page 21 
100 See Section 5, starting on page 42 
  54 
is required (most likely to process expanded test volume), the province should reconsider 
the economics of privately owned solutions (privatizing MGL or outsourcing testing to 
private laboratories). 
Whether MGL is funded by a pure per-test system or a mixed system where 
global funding is used for salaries (and adjusted upward annually to account for step 
increases and promotions) and the consumables budget is increased on a per-test basis 
depends upon the flexibility of the provincial accounting systems.  Either will meet the 
basic requirement of ensuring appropriate funding for MGL through the near future.  A 
mixed system is preferable from a psychological point of view. 
A per-test budget over five years for MGL should total no more than $10M - 
$18M and will probably be less as per-test costs decline with learning curves and 
economies of scale. 
6.1.2 Reducing OOC Payments 
The 2008/9 budget adjustment for MGL begins the process of reducing OOC 
payments by developing new tests.  The Ministry of Health should track tests sent out of 
province and develop in-province capability for the most common (and expensive) tests.  
To facilitate this process, some individual entity should be responsible for tracking all 
Ministry of Health funded genetic testing.  The Director of MGL should receive monthly 
tracking data (type of tests, number of tests, and cost of tests) on all covered out-of-
province genetic tests in order to plan test development. 
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6.2 Additional Steps 
Although I have satisfied my basic project requirements to establish a balanced 
funding strategy for MGL over the next five or more years, to reduce referred out 
expenses, and to present and justify a sustainable and affordable approach to funding 
genetic testing in B.C., there are some additional items which have come to my attention 
as potential issues in the future implementation of this funding strategy.  I present them 
here as issues to be explored, with prospective solutions where I have them. 
6.2.1 Accounting and Tracking 
MGL does not appear to have proper access to accounting and test tracking 
information.  The Director should have instant access to basic financials (salaries, 
equipment costs, supply costs, etc.) and test cost (hours and supplies) and frequency, as 
well as information on number and frequency of referred-in tests and tests sent out of 
province (and whether they are sent out for reasons of capacity constraint or lack of an in-
province test).  This information is limited enough that a simple dashboard could almost 
certainly provide it. 
To facilitate decisions about new tests and whether it is cost-effective to develop 
new tests and/or send tests out of province, all DNA based tests covered by MSP should 
be tracked and the information made available for analysis.  A single storage database 
would be best, but aggregation is an acceptable alternative. 
In order to adequately meet Criterion 4 (Sound Business Practices), better 
accounting and test tracking systems must be put in place.  Because MGL is the primary 
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actor in B.C. genetic testing, it makes sense that the tracking function be added to MGL 
along with sufficient funding, equipment, and personnel to perform it. 
6.2.2 Priorities 
If MGL is allowed by the Ministry of Health to expand referred-in revenue by 
widely offering tests to out-of-province clients, priorities must be clearly established.  
Because MGL exists primarily for the benefit of the people and province of B.C., tests 
covered by the MSP must receive priority over uncovered or out-of-province tests.  
However, exceptions must be possible in cases where the uncovered or out-of-province 
tests are critical to immediate decisions about life-threatening conditions and the covered 
tests are not.  The revenue from uncovered or out-of-province tests must not be allowed 
to displace covered tests, but there may be valid medical reasons to do so.  A group of 
medical specialists and ethicists should be convened to establish priorities and the 
guidelines for exceptions. 
6.2.3 Intellectual Property Issues 
Because the value of genetic and genomic testing and treatment is represented by 
information, intellectual property law generally applies.  Because we, as a society, 
consider ownership of some living things (humans, for example) to be morally repugnant, 
moral questions as to the legal ownership of genetic and genomic information arise.  
Because privacy, identity, and identity theft are increasingly interesting topics of legal 
and moral discussion, the ability of DNA to unequivocally identify a specific individual 
is both a legal and moral issue. 
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All these concerns are entwined with the questions of who owns genetic/genomic 
information and who should be allowed access to genetic/genomic information. 
6.2.3.1 Patents on Genetic Discoveries 
Although links between genome variations and disease are discoveries and not 
inventions, patents are nonetheless being issued by some jurisdictions covering the 
linkage between DNA variations and diseases.  Individual jurisdictions are making ad 
hoc decisions about whether or not to honour those patents on either legal or 
humanitarian grounds.  British Columbia should formally examine this question and 
resolve it so that clinicians, genetic counsellors, and the MGL have proper legal 
guidance. 
6.2.3.2 Ownership of Genetic Information 
Whether or not individuals own their genetic/genomic information remains 
unresolved.  Once again, B.C. should formally examine this question and resolve it so 
that individuals and genetic researchers have proper legal guidance. 
6.2.3.3 Privacy of Genomic Information 
A full genome is the ultimate in personal information, but it cannot be easily used 
to identify an individual (that is, you cannot say, given a genome, that it belongs to X 
person).  It can be used only to confirm the identity of an individual.  As such, genome 
data deserves careful protection but not absolute protection.  The question of exactly how 
much protection should be examined and established so that proper guidelines can be 
provided to laboratories and researchers. 
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6.2.3.4 Research Uses of Genomic Information 
Genomic information has incredible potential for research.  Predictive and 
diagnostic testing can be matured through data mining techniques if sufficient numbers of 
genomes and their accompanying phenotype information (in this case, diseases and 
syndromes) are made available for research.  Full genome information can be used to 
conclusively identify an individual, which argues for careful protection of genomes.  
Aggregated genome information may open up new vistas in medical treatment, which 
argues for widespread research using genomic information.  Genetic researchers, medical 
ethicists, legal experts, and computer security experts should determine how to balance 
protection with research. 
6.2.4 MSP policy on Predictive genetic testing 
MSP’s policies currently specifically exclude predictive genetic testing for 
coverage.  As genomic medicine matures, predictive testing will become more and more 
valuable.  Knowing whether an individual has a heightened risk of diabetes, for instance, 
could save the province considerable expense by delaying the onset of disease through 
careful management.  Such information will be available soon through predictive testing.  
B.C.’s Ministry of Health should examine the question of when predictive genetic testing 
will be cost-effective and reliable enough to cover, and put in place systems to approve 
specific predictive tests. 
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APPENDICES 
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Appendix A: Prevalence of Genetic Diseases 
Establishing the prevalence or incidence of genetic diseases is not an exact 
science.  Various sources report differing values, so all calculations have been done using 
a combination of low and high values.  As appropriate, prevalence is relative to 
population, birth rate, or birth rate by sex.  Many genetic disorders have varying 
prevalence by the geographic or genetic origin of the population.  Wherever possible, I 
have used figures corresponding to Caucasian and Asian populations to reflect the genetic 
diversity of B.C. and especially Vancouver. 
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 Overall Male Births Female Births 
 Low High Low High Low High 
Original Menu             
□ Achondroplasia    1/40000      1/15000        
□ Angelman Syndrome    1/20000      1/10000        
□ Beta Thalassemia    1/114000     1/2600         
□ CADASIL    1/50000      1/50000        
□ Charcot Marie Tooth 1A    1/3300       1/3300         
□ Connexin 26-deafness    7/50000      7/50000        
□ Cystic Fibrosis    1/3900       1/3900         
□ Duchenne/Becker Muscular 
Dystrophy 
     1/5600        
□ Fragile X    1/8918       1/3600       1/6000       1/4000    
□ Friedreich Ataxia    1/50000      1/25000        
□ Hemoglobin S,C    1/600        1/400          
□ Hemophilia A (F8)    1/10000      1/10000        
□ Hereditary Multiple Exostosis    1/100000     1/50000        
□ Hereditary Neuropathy w/Liability to 
Pressure Palsies  
   1/50000      1/20000        
□ Huntington Disease     1/1000000    7/100000       
□ Hypochondroplasia    1/28000      1/26000        
□ Myotonic Dystrophy I    1/100000     1/8000         
□ Prader-Willi Syndrome    1/15000      1/10000        
□ Spinalmuscular Atrophy    1/25000      1/25000        
□ X-Linked Ichthyosis-STS Deficiency    1/6000       1/6000            
Added June 2008        
Angelman    1/20000      1/10000        
Craniosynostosis    1/3000       1/2000         
HHT    1/5000       1/5000         
LQTS    1/10000      1/2500         
Marfan    1/5000       1/5000         
Neurofibromatosis 1    1/3000       1/3000         
Neurofibromatosis 2    1/25000      1/25000        
Rett    1/12500      1/12500        
Speculative Future Tests             
Crohn's    1/1000       1/544          
Sporadic ALS    3/100000     1/12500        
CYP2D6 Polymorphism   19/1000      77/1000            
Table 17: Known Prevalence of Genetic Diseases 
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Sources: 
http://en.wikipedia.org/wiki/Achondroplasia#cite_note-pmid17879967-0 
http://www.healthatoz.com/healthatoz/Atoz/common/standard/transform.jsp?requestURI=/healthatoz/Atoz/
ency/thalassemia.jsp 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/AR_Sensorineural_Hearing_Loss_(DFNB
1/Connexin_26)#Prevalence 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Cystic_Fibrosis_Carrier_Screening-2 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Duchenne_Muscular_Dystrophy-1 
http://ovidsp.tx.ovid.com.proxy.lib.sfu.ca/spb/ovidweb.cgi?&S=GBMCFPFAMIDDMIMAMCHLAHOKE
PPPAA00&Complete+Reference=S.sh.15.16.18|6|1 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Friedreich_Ataxia#Incidence_and_Carrier
_Frequency 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Sickle_Cell_Anemia 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Hemophilia_and_Von_Willebrand_Diseas
e#Hemophilia_A 
http://en.wikibooks.org/wiki/Diagnostic_Radiology/Musculoskeletal_Imaging/Tumors_Basic/Hereditary_
Multiple_Exostoses 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Hereditary_Neuropathy_with_Liability_to
_Pressure_Palsies_(HNPP)_and_Lobular_Carcinoma_In_Situ_(LCIS) 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Achondroplasia-1#Incidence 
http://www.myotonicdystrophy.org/General%20Information.htm 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Prader-Willi_Syndrome-2#Incidence 
http://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Spinal_Muscular_Atrophy_(SMA1)#Incid
ence, http://en.wikipedia.org/wiki/Twin 
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Appendix B: C&W Molecular Genetics Test Menu 
CW Molecular Genetics Test Menu 
□ Achondroplasia 
□ Alpha Thalassemia 
□ Angelman Syndrome 
□ Ashplex panel: tay sachs, canavan,  
        fanconi anemia, familial  dysautonomia 
□ Beta Thalassemia 
□ CADASIL 
□ Charcot Marie Tooth 1A 
□ Chimerism-bone marrow 
□ Connexin 26-deafness 
□ Cystic Fibrosis 
□ Duchenne/Becker Muscular Dystrophy 
□ Dystonia (early-onset primary) 
□ Familial Mediterranean Fever 
□ Fascioscapulohumeral Dystrophy 
□ Fragile X 
□ Friedreich Ataxia 
□ HFE 1 Hemochromatosis 
□ Hemoglobin S,C 
□ Hemolytic Disease Newborn - Rh, Kidd, Kell, Duffy 
□ Hemophilia A (F8) 
□ Hereditary Multiple Exostosis 
□ Hereditary Neuropathy with Liability to Pressure Palsies  
□ Heterotaxy (X-Linked) 
□ Huntington Disease  
□ Hyperkalemic Periodic Paralysis 
□ Hypokalemic Periodic Paralysis 
□ Hypochondroplasia 
□ Linkage Analysis-CF, F8, DMD 
□ Myotonic Dystrophy (Type 1) 
□ Non-Ketotic Hyperglycinemia 
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□ Oculopharyngeal Muscular Dystrophy 
□ Platelet-Specific Alloantigen (P1A1) 
□ Prader-Willi Syndrome 
□ Progressive Myoclonus Epilepsy 
□ Spinal Muscular Atrophy 
□ SpinoBulbar Muscular Atrophy 
□ Spinocerebellar Ataxia  
□ Thanatophoric Dysplasia 
□ Transthyretin Amyloidosis 
□ Uniparental Disomy 6, 7, 14, 15 
□ X-Linked Ichthyosis-STS Deficiency 
□ Zygosity 
□ DNA extraction only 
Table 18: C & W Molecular Genetics Test Menu 
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Appendix C: C&W Cytogenetics Test Menu 
CW Cytogenetics Test Menu 
Karyotype Analysis 
□ Karyotype Analysis of Peripheral Blood 
□ Karyotype Analysis of Amniotic Fluid 
□ Karyotype Analysis of CVS 
□ Karyotype Analysis of Pediatric Bone Marrow 
□ Karyotype Analysis of Pediatric Tumours 
□ Karyotype Analysis of Tissue 
□ Karyotype Analysis of Products of Conception 
□ Karyotype Analysis of malignant effusion 
□ Karyotype Analysis of Fetal Blood 
□ High Resolution Karyotype Analysis 
□ Chromosomal Mosaicism 
□ Chromosomal Breakage Studies 
□ Chromosomal Special Banding 
□ Chromosomal Special Staining 
□ Culture for Biochemical or Molecular Analysis 
 FISH Analysis 
□ Uncultured Amniocyte Aneuploidy Screen 
□ XX/XY FISH Chimerism Testing 
□ CGH 
□ Interphase Chromosome Enumeration  
□ Interphase Sex Chromosome Enumeration  
□ MFISH 
□ Sub-Telomeric Region Testing 
 
Oncology Tests 
□ 13q14 (RB1) Testing 
□ AML1/ETO Fusion Testing 
□ BCR/ABL Fusion Testing 
□ CBFB Rearrangement Testing 
□ Chromosomes 4,10 and 17 Enumeration 
□ ETV6 Rearrangement Testing 
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□ EWSR1 Rearrangement Testing 
□ FKHR Rearrangement Testing 
□ Chromosome 5 Monosomy/ Deletion 5q Testing 
□ Chromosome 7 Monosomy/Deletion Testing 
□ MLL Rearrangement Testing 
□ N-MYC Amplification Testing 
□ p16 Gene Deletion Testing 
□ TEL/AML1 Fusion Testing 
Microduplication/deletion Testing 
□ 21q22.2 Region Testing 
□ 22q11.2 and 22q13.3 Region Testing 
□ 1p36 Deletion Testing 
□ Alagille Syndrome Testing 
□ Angelman Syndrome Testing 
□ Cri-du-Chat Syndrome Testing 
□ Kallmann Syndrome Testing 
□ Miller-Dieker Syndrome Testing 
□ NF1 Gene Deletion Testing 
□ PAX6 Gene DeletionTesting 
□ Prader Willi Syndrome Testing 
□ Smith-Magenis Syndrome Testing 
□ SNRPN Deletion Testing 
□ SNRPN Duplication/Deletion Testing 
□ Sotos Syndrome Testing 
□ SRY Gene Testing 
□ Steroid Sulfatase Deficiency Testing 
□ Willliams Syndrome Region Testing 
□ Wolf-Hirschhorn Syndrome Testing 
Table 19: C&W Cytogenetics Test Menu 
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Appendix D: C&W Biochemical Genetics Mitochondrial DNA Test 
Menu 
Biochemical GeneticsTest Menu: Mitochondrial DNA 
Testing 
□ LHON   Leber's mtDNA Mutation (11778,14484,3460)     
□ LHON-Dystonia mtDNA mutation (14459)                  
□ Long PCR mtDNA Deletion                              
□ MELAS mtDNA Mutation (3271 & 3243)                    
□ MERRF mtDNA Mutation (8344)                           
□ NARP mtDNA Mutation (8993)                     
□ Southern Blot mtDNA Deletion 
Table 20: C&W Biochemical Genetics Mitochondrial DNA Test Menu 
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Appendix E: C&W Biochemical Genetics Test Menu 
Biochemical GeneticsTest Menu: Inborn Errors in 
Metabolism Assays 
□ Acylcarnitine Profile,  Serum                               
□ Acylcarnitine Profile, blood dot card                         
□ Alpha-Galactosidase (Fabry),WBC                   
□ Alpha-Iduronidase (Hurler),WBC                                
□ Amino Acids, Urine 
□ Amino Acids,CSF 
□ Amino Acids,Plasma 
□ Aryl Sulfatase A (Metachromatic leukodystrophy),WBC  
□ Aryl Sulfatase C (X-linked ichthyosis),WBC                    
□ Beta-Galactosidase (GM1),WBC                                 
□ Beta-Glucosidase (Gaucher),WBC                                   
□ Biotinidase,Serum 
□ Carnitine,Serum 
□ Cell Culture (skin, fibroblast propagation, AFC) 
□ CPT1a,P479L Variant, Blood Dot Card 
□ DNA Extraction (blood, tissue, fibroblast) 
□ Galactocerebrosidase (Krabbe) Enzyme,WBC              
□ Hexosaminidase (Tay-Sachs disease/carrier status),Serum 
□ Mitochondrial Respiratory Chain Enzymes, muscle (Complexes I, II, IV & citrate synthase) 
□ Mucopolysaccharide,Urine                                  
□ Oligosaccharides,urine                                        
□ Quantitative organic Acids, Urine 
□ Sphingomyelinase (Niemann-Pick A/B) ,WBC 
□ Transferin Isoelectric focusing, serum 
□ Urine Purines & Pyrimidines (includes creatine, creatinine and GAA to investigate for creatine 
synthetic and transporter defects) 
□ WBC Preparation, whole blood 
□ Alanine-Glyoxylate Aminotransferase (Hyperoxaluria type I),Liver   
□ Alpha-Fucosidase,WBC                       
□ Alpha-Mannosidase,WBC                           
□ Aryl Sulfatase B (MPS VI),WBC                                   
□ Beta-Glucuronidase (MPS VII),WBC                               
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□ Beta-Mannosidase,WBC                                  
□ Iduronate sulfatase (Hunter) enzyme, Serum 
□ Hexosaminidase,WBC 
□ Mycoplasma, culture supernatant 
□ San Filippo Type B (MPS III),Serum 
□ San Filippo Type C (MPS III) ,WBC 
□ Sulfocysteine, Urine 
Table 21: C&W Biochemical Genetics Test Menu 
  70 
Appendix F: June 2008 Tests to be Added 
• Angelman Syndrome 
• Craniosyostosis Syndromes 
• Hereditary Hemorrhagic Telangiectasia (HHT) 
• Infantile Epilepsy 
• Long QT Syndrome 
• Margan Syndrome 
• Neurofibromatosis Type 1 
• Neurofibromatosis Type 2 
• Pendred Syndrome 
• Periodic Fever Syndrome 
• Rett Syndromes 
• RYR2-related Cardiac Disease 
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Appendix G: Mission Statements and Goals 
At the program level: 
The Provincial Medical Genetics Program is committed to providing high 
quality genetic health care to residents of B.C., while participating in and 
contributing actively to research and education in the field of Medical 
Genetics.  We seek to fulfill this role in accordance with the missions of 
the Children's and Women's Heath Centre of B.C., the Provincial Health 
Services Authority and the University of British Columbia.101 
At the department level: 
The Department of Pathology & Laboratory Medicine at Children’s & 
Women’s Health Centre of British Columbia provides critical tertiary-care 
diagnostic consultation and services on which vital decisions are made in 
the care of patients. It is also dedicated to research and teaching in 
paediatric and obstetric laboratory medicine through the application of 
specialized consultative expertise in diagnosis, screening and 
monitoring.102 
At the provincial level, the goals and objectives of the Ministry of Health include: 
Goal 1: Improved Health and Wellness for British Columbians… 
Objective 1: Individuals are supported in their efforts to stay healthy and 
make healthy lifestyle choices… 
Objective 2: Protection of the public from preventable disease, illness and 
injury… 
Goal 2: High Quality Patient Care… 
Objective 2: Patient-centred care tailored to meet the specific health needs 
of patients and specific patient groups… 
Goal 3: A Sustainable, Affordable, Publicly Funded Health System… 
                                                
101 B.C. Women's Hospital & Health Centre. (2008). Medical Genetics. Retrieved 2008.06.27 
102 U.B.C. Department of Pathology & Laboratory Medicine. (2008). Research Programs. Retrieved 
2008.07.04, http://www.pathology.ubc.ca/html/BCCH.html 
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Objective 4: Sound business practices to manage within the available 
budget while meeting the priority needs of the population.103 
                                                
103 B.C. Ministry of Health. (2006). 2006/7 - 2008/9 Service Plan. Retrieved 2008.06.27,, pp 20 - 33 
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Appendix H: MSC Guidelines on Genetic Tests 
6. Laboratory and Medical Imaging Tests   
a) Funding will not be provided for experimental or developmental 
laboratory and medical imaging tests where the efficacy of such services is 
not known.    
b) In order for proven laboratory and medical imaging tests to be funded 
out of country, all diagnostic avenues in B.C. and Canada must have been 
exhausted. 
c) If laboratory and medical imaging tests are not available in Canada, but 
are of proven value, prior approval will be given by MSP only if the result 
of the test would significantly alter the management of the beneficiary's 
condition. In limited circumstances, US Food and Drug Administration 
(FDA) approved laboratory and medical imaging processes may be 
deemed medically necessary if promising outcomes have been 
substantiated by reputable clinical trials, beyond Phase III published in 
peer reviewed medical literature.   
d) It is the responsibility of the appropriate medical specialist making 
application on behalf of a beneficiary for prior approval of funding for out 
of country laboratory and medical imaging tests to provide MSP with peer 
reviewed medical literature about the laboratory and medical imaging tests 
requested. 
7. Genetic Tests   
Predictive genetic testing is not an insured service for beneficiaries of 
MSP in British Columbia, and is therefore not funded when performed 
outside of Canada. Genetic testing is an insured service in British 
Columbia only when it is medically necessary to the medical management 
of the beneficiary's condition.104 
 
                                                
104 Medical Services Commission. (2006). Medical Services Commission Out of Province and Out of 
Country Medical Care Guidelines for Funding Approval. Retrieved 2008.07.05, 
http://www.health.gov.bc.ca/msp/infoben/ooc_funding_guidelines.pdf, pg 5. 
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